This article is co-authored by a patient with metastatic hormone-sensitive prostate cancer who is receiving abiraterone and androgen deprivation therapy treatment in Manchester, UK. The patient relates his personal experiences struggling with the diagnosis, his experience with treatment and the physical, emotional and psychosexual impact on his life. After his diagnosis, the patient has become an outspoken advocate and fundraiser for prostate cancer awareness and wants to ensure that novel treatments with proven efficacy and tolerability, such as abiraterone, are available for all men in his condition. The specialist nursing and physician perspectives, provided by healthcare professionals based in London who are not directly involved in this patient's care, were written in response to the challenges and concerns highlighted by this patient. The role of the specialist nurse as a key healthcare professional in the cancer patient journey, particularly in managing the complex physical and emotional side effects of treatment, is highlighted in this perspective piece. The physician reviews the current difficulties of establishing an effective screening programme in prostate cancer, the common side effects of hormone treatment and the significant progress and challenges in novel drug development and prescription in metastatic hormone-sensitive prostate cancer. While written primarily from the perspective of a patient and healthcare professionals in England, many messages in this commentary would resonate with patients and professionals involved in the care of prostate cancer worldwide.

Oncology and therapy. 2020 Oct 09 [Epub ahead of print]

Tony Collier, Shievon Smith, Michelle Greenwood, Kenrick Ng

Prostate Cancer UK, 53 Tooley Street, London, SE1 2QN, UK., St Bartholomew's Hospital, Barts Health NHS Trust, London, EC1A 7BE, UK., St Bartholomew's Hospital, Barts Health NHS Trust, London, EC1A 7BE, UK. .

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33037517

Continued here:
Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and...

Recommendation and review posted by Bethany Smith

Though COVID-19 has stopped many things this year, it hasnt stopped other life-threatening illnesses during Breast Cancer Awareness Month.

Some may be putting off an annual wellness visit or other medical procedures because they dont want to be in a medical center during the pandemic, but American Cancer Society Senior Community Development Manager Kim Durst says breast cancer and other diseases shouldnt be ignored, So if you are concerned because maybe you found a lump or its that time for you to go in and get your testing done, reach out to your healthcare provider. They are taking the precautions at the doctors offices, hospitals, and clinics where you wear your mask, use your hand sanitizer, and they are finding ways now to get people in for their checkups.

The Centers for Disease Control and Prevention states that additional ways to lower your risk of breast cancer include keeping a healthy weight and exercising regularly, limiting alcohol consumption, and asking your physician about the risk of taking hormone replacement therapy or birth control pills.

Read more from the original source:
Schedule Your Breast Cancer Screening this Month - raccoonvalleyradio.com

Recommendation and review posted by Bethany Smith

Olaparib (Lynparza) significantly improved overall survival (OS) versus enzalutamide (Xtandi) or abiraterone acetate (Zytiga) in patients with metastatic castration-resistant prostate cancer (mCRPC) who harbor BRCA1, BRCA2, and/or ATM aberrations, according to results from the final OS analysis of the pivotal phase 3 PROfound trial (NCT02987543).1

In the trial, patients with mCRPC who progressed on previous treatment with a new hormonal agent and harbored BRCA1, BRCA2, or ATM aberrations (n = 245; cohort A) or other alterations in the homologous recombination repair (HRR) pathway (n = 142; cohort B) were randomized 2:1 to receive either olaparib or enzalutamide or abiraterone acetate.

Final OS data from cohorts A and B were presented during the 2020 ESMO Virtual Scientific Program. Results showed that the median OS in cohort A was significantly longer with olaparib than with physicians choice (HR 0.69; 95% CI 0.50-0.97; P = .0175).1In cohort B, the median OS was 14.1 months with olaparib versus 11.5 months with the control (HR, 0.96; 95% CI, 0.63-1.49).

What is exciting about this particular trial is that it showed the feasibility of personalizing care and using precision medicine strategies to preselect patients to maximize the chance of benefit for those who are candidates for these treatments, said Maha H.A. Hussain, MD, FACP, FASCO.We can also help patients avoid unnecessary exposure to ineffective treatments.

Previously published data showed that olaparib resulted in a 66% reduction in the risk of disease progression or death compared with abiraterone or enzalutamide (HR, 0.34; 95% CI, 0.25-0.47;P<.0001).2 Based on these results, the FDA approved olaparib in May 2020 for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR genemutated mCRPC who have progressed following prior treatment with enzalutamide or abiraterone.

In an interview with OncLive, Hussain, the Genevieve E. Teuton Professor of Medicine in the Department of Medicine of the Division of Hematology Oncology and the deputy director at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine, further discussed the updated findings from the PROfound trial, its clinical significance in the treatment of patients with mCRPC paradigm, and the promise of precision medicine.

Hussain: PROfound is a randomized phase 3 clinical trial. It is one of the first precision medicine clinical trials to complete; patients were preselected based on specific genomic alterations and then randomized accordingly. Patients with mutations in the HRR genes or DNA damage repair genes were assigned to 2 different cohorts. The primary cohort was [comprised of] patients who had BRCA1/2 or ATM mutations, while cohort 2 included [those who harbored] other genes that are involved in the HRR pathway. Patients were randomized 2:1 to olaparib or standard of care per physicians choice of either abiraterone and prednisone or enzalutamide. The primary end point [of the trial] was radiographic progression-free survival (rPFS), which is a meaningful clinical end point, while OS was one of the several key secondary end points [examined].

Data from the Stand Up to Cancer highlighted the fact that over 20% of patients with mCRPC have significant mutations in the DNA repair pathway or the HRR genes. That [research] underscored the fact that this is a clinically relevant pathway to go after. At the time that [the PROfound trial was being designed] we saw evidence of benefit [with this approach] in other tumors [such as] breast and ovarian cancers, and then subsequently, in pancreatic cancer.

The specific pathway relevance is that both normal cells and cancer cells need to repair themselves when there is damage; the HRR pathway is involved in that repair process. However, are alterations or mutations [are present], the cells are not able to repair themselves and they fall back into a different pathway, which is the PARP pathway. Basically, PARP agents tend to inhibit that enzyme so that the [cancer] cells cannot repair themselves.

[Earlier data from the trial were previously published] this past summer. Johann de Bono, MB, ChB, PhD, of The Institute of Cancer Research was the first author on the publication in the New England Journal of Medicine, which highlighted [data regarding] the primary end point of rPFS. In this particular presentation delivered at the 2020 ESMO Virtual Congress, [investigators] reported OS [data from] cohorts A and B.

We saw that the benefit [with olaparib is] not only in terms of rPFS; the benefit translated into a median OS benefit of over 4 months between the arms, despite crossover from the control arm to the olaparib arm at time of progression. Additionally, the risk of death was reduced by 31%, which is very clinically significant. In [the cohort of patients who harbored the] other 12 genes, other than BRCA1/2 and ATM, we saw a trend in OS improvement but it was not statistically significant. The trend was about a little bit over 2 months of a difference. When adjusting for crossover, the trend improved although it was still not statistically significant. However, several patients in cohort B experienced clinical benefits from treatment. The primary benefit [with olaparib] still seems to be driven by BRCA primarily.

No; the overall safety was very much consistent with what was known about olaparib. The most common adverse effects observed included anemia, nausea, and fatigue. Most of these were low-grade events, aside from the anemia. Many of these patients were heavily pretreated; while they might have previously received abiraterone or enzalutamide, they would have also received chemotherapy and other potential anticancer treatment and be fairly advanced in the course of their disease. The findings, overall, are really not surprising and the safety profile very much consistent with what has been observed with the agent in other tumors.

We have reached a major benchmark in the management of this disease. Ever since the original observations regarding androgen deprivation [therapy] in prostate cancer and subsequent treatments, and certainly since the time I entered the field in the early 1990s, prostate cancer management has been more of a one-size-fits-all approach. In fact, when we give chemotherapy and hormone treatment we don't preselect [patients].

We still have [a lot of work to do]. Patients with metastatic castration-resistant disease continue to die from prostate cancer; they also suffer from pain and other factors involved with this disease. This [research] highlights the feasibility of performing precision medicine trials. It also shows us that meaningful clinical benefits could be achieved in these patients. I would hope that our partners across the spectrum will invest further in conducting more clinical trials.

The observation that we've seen with olaparib also opens up the door for potential combination clinical trials, both in castration-resistant disease and potentially in earlier stages of disease, where we might get a better return on investment from a clinical perspective.

Genomic profile evaluation for patients is critical moving forward, not only for the purpose of treatment for the patient. Conducting or counseling the patient regarding germline testing and tumor genomics evaluation in preparation for future treatment is also very critical. Obviously, genetic testing is associated with genetic counseling, [which may allow patients] and potential blood relatives [to get ahead of the game].

Tissue-based genomic evaluation will open the door for the patient to explore different treatments, and [certain] genomic alterations might qualify them for different clinical trials opportunities. [This work] underscores the hope for patients that their cancer can be managed better with genomically targeted treatments, specifically, in this case, the PARP inhibitor. [Now we can build on] these observations in terms of different treatment strategies and combinations.

Read the original here:
PROfound Trial With Olaparib Shows Feasibility of Personalizing Care in mCRPC - OncLive

Recommendation and review posted by Bethany Smith

NEW YORK, Oct. 12, 2020 /PRNewswire/ --Nutrafol, the award-winning hair wellness supplement backed by top physicians, celebrities and hairstylists alike, announces the positive results from its new clinical trial, an industry-first study presented on hair growth in menopausal women. The 6-month double-blind, randomized, placebo-controlled study assesses the safety and efficacy of Nutrafol's Women's Balance formulation in improving hair growth and quality in perimenopausal, menopausal and postmenopausal subjects with self-perceived thinning hair. This milestone establishes Nutrafol as the only hair supplement brand to present research specifically for menopausal women and continues to solidify Nutrafol as an innovator and trusted leader in hair science.

Forty percent of women experience hair loss by age 40, and that number continues to increase as women age.1 Nutrafol created Women's Balance - which first launched in 2019 - in response to the complex hormonal needs of women who are going through or have gone through menopause. It is the only hair wellness supplement clinically formulated to address the root causes of hair thinning in perimenopausal and menopausal women. Featuring a patented Synergen Complex Plus, it includes clinically effective natural ingredients like saw palmetto, ashwagandha and maca, known to support hormone health before, during and after menopause.

"There is unfortunately a lack of research for the physical and emotional effects that menopause has on women," said Dr. Sophia Kogan, Nutrafol's co-founder and Chief Medical Advisor. "At Nutrafol, our mission is to empower women to take control of their hair health, and hormones. After years of research, rigorous clinical testing and the accumulation of unsurpassed data, we have a proven and effective option with our Women's Balance formulation."

To assess the safety and efficacy of Women's Balance for perimenopausal, menopausal and postmenopausal women, Nutrafol conducted a 6-month randomized, double-blind, placebo-controlled trial. Results were significant for objective measures of hair growth, including terminal, vellus and total hair counts. There was a progressive increase in hair counts for Nutrafol subjects compared to placebo at three and six months. Additionally, daily administration of Nutrafol resulted in significantly less shedding compared to placebo. This was accompanied by significant visible clinical improvement in hair growth and quality in the active group, as assessed by a blinded physician investigator. Conclusively, the study verified that the daily intake of a novel supplement with bio-optimized phytoactive ingredients to specifically address multiple underlying factors that compromise hair growth was safe and effective in improving hair growth and quality in women going through menopausal transition. The Primary Investigator of the study was Dr. Glynis Ablon, MD, FAAD and founder of the Ablon Skin Institute & Research Center, an independent clinical research site specializing in dermatology clinical trials.

"Menopause is a disruptive time for women between the hormonal shifts and changes in their bodies that are out of their control," said Dr. Glynis Ablon MD, Primary Investigator on the clinical study. "Nutrafol has pioneered a new way of thinking about the science of hair wellness as it relates to menopause. With safety and efficacy at the forefront of everything the brand does, the published data supports the clinical effectiveness of the Women's Balance formulation for menopausal women. This provides physicians with a solution for their patients, and gives menopausal women the opportunity to take control of their menopausal transition and beyond."

To learn more about Nutrafol and Women's Balance, please visit http://www.Nutrafol.com or speak with your Healthcare Provider.

About NutrafolNutrafol pioneered the hair wellness category with its integrative approach to hair health, using a first-of-its-kind patented formulation of clinically effective, natural, medical-grade ingredients to support whole body wellness from within. In multiple clinical studies, Nutrafol has been shown to improve hair growth in both men and women by multi-targeting root causes of thinning hair, including stress, hormones, environment and nutrition. Nutrafol's team of doctors and researchers continue to seek out scientific advancements at the forefront of genetics, anti-aging medicine, phytoactive and biotechnology to remain on the cutting-edge of hair health innovation. Nutrafol has been adopted by over 2,700 Healthcare Providers across the U.S. for its trusted, reliable results and has received numerous prestigious accolades.

1American Academy of Dermatology

PR ContactBehrman Communications / Gianna Cesa[emailprotected] 212.986.7000

SOURCE Nutrafol

http://www.nutrafol.com

More:
Nutrafol Pioneers Hair Wellness Industry with New Study that Reveals it Safely and Effectively Improves Hair Growth in Menopausal Women - PRNewswire

Recommendation and review posted by Bethany Smith

Jennifer Wong, RPA-C

ASTORIA, N.Y. (PRWEB) October 14, 2020

Blame it on the hormones? Well, maybe. In some cases, notes Jennifer Wong, a certified registered physicians assistant specializing in dermatology with Advanced Dermatology PC, the dark skin patches called melasma occur at the same time a woman experiences hormonal changes. But were still learning about the nature of the connection.

In this country, as many as six million people a year ninety percent of them women experience darkened patches of facial skin, usually brown or gray, the result of overproduction of the skin pigment melanin.

In particular, says Wong, women with darker skin tones are more susceptible because their skin has more active melanocytes the skin cells that produce melanin. Genetics also seems to play a role: having a family member with melasma increases the possibility of developing it yourself.

And, of course, there is the role of the sun. The sun triggers our melanocytes, observes Wong. With melasma, very little exposure may cause the discoloration. Unlike age spots, melasma is not due to cumulative sun, and actually often occurs in young women. In some cases, even the light of our computer or cell screens can contribute to melasma.

Melasma usually appears on the center forehead, over the brows, on the bridge of the nose, on the chin, and on the upper lip. All places that get sun exposure, observes Wong. In some cases, melasma occurs on other frequently exposed areas like our forearms.

When melasma co-occurs alongside hormonal changes due to pregnancy, birth control pills, or hormone replacement, it can spontaneously resolve when hormones return to previous levels, for example after the pregnancy or if medications are discontinued. But in other cases, notes Wong, melasma persists. While it is medically harmless, its appearance on ones face can be distressing. Fortunately, we have a number of options to lighten melasma.

With that in mind, Wong makes the following suggestions:

5 Tips on Treating Melasma:

1. First, get a clear diagnosis: Its important, says Wong, to rule out any skin condition that requires medical treatment. A skin specialist can do an examination and, if needed, a biopsy. Once you have a clear diagnosis, you can work with your provider on a treatment plan.

2. Skin lighteners can help: In particular, notes Wong, topical use of hydroquinone or HQ can be effective. HQ comes in varying strengths, including less concentrated over-the-counter formulations, as well as combined with other topicals, such as the retinoid tretinoin and a corticosteroid, in a so-called triple cream. Other topical lighteners include azelaic acid and kojic acid. Your skin-care specialist can help guide your choices.

3. Choose OTC products with care: An alarming number of OTC skin lighteners contain mercury, advises Wong, a neurological toxin that can also injure the children and partners that people come into close contact with. Your skin specialists guidance can be especially helpful because some products do not clearly identify ingredients, using different terms for mercury, including calomel, cinnabaris, hydrargyri oxydum rubrum, or quicksilver. In addition to hidden mercury, weve also seen products with unlisted steroids, which can cause skin damage.

4. Outpatient procedures can help, too: Lasers, explains Wong, can penetrate down to melanocytes to block melanin production, while chemical peels can remove hyperpigmented surface skin. Again, your skin specialist can explain outcomes, time involved, and side effects to help customize a treatment plan that is the best fit.

5. Throw shade on the chance of reoccurrence: The sun activates our skins production of melanin, notes Wong. Melasma can be triggered by minimal exposure, regardless of season or weather, so patients will want to be vigilant about protecting themselves from the sun every day, all year. A broad-spectrum SPF 30 mineral sunscreen with zinc oxide or titanium dioxide can help physically block rays. Patients will also benefit from protective clothing, including a wide-brimmed hat and sunglasses.

Fortunately, Wong concludes, patients can take action now to reduce the appearance of melasma, as research continues to connect the dots between hormones and other factors.

Bio: Jennifer M. Wong, RPA-C Physician Assistant. Ms. Wong has comprehensive experience in medical and cosmetic dermatology for all ages.

Advanced Dermatology P.C. and the Center for Laser and Cosmetic Surgery (New York & New Jersey) is one of the leading dermatology centers in the nation, offering highly experienced physicians in the fields of cosmetic and laser dermatology as well as plastic surgery and state-of-the-art medical technologies. http://www.advanceddermatologypc.com

View original post here:
Jennifer Wong, RPA-C with Advanced Dermatology PC, Offers Tips on Reducing the Hyperpigmentation of Melasma - PR Web

Recommendation and review posted by Bethany Smith

Katherine Crew, MD, is a physician-scientist whose work in breast cancer risk, prevention, and screening has helped move the needle in breast cancer research. Dr. Crew is a member of the Cancer Population Science research program at the Herbert Irving Comprehensive Cancer Center, associate professor of medicine and of epidemiology at Columbia University Irving Medical Center, and a medical oncologist at NewYork-Presbyterian Hospital.

Weve made a lot of strides in the past few decades and part of that is because we are detecting breast cancer a lot earlier with improved screening and due to our improvements in treating breast cancer, says Dr. Crew. There are always more improvements to make along the way but overall survival for breast cancer, since the 1980s, has improved by about 40%, and its due to all of those efforts, including increased advocacy and increased awareness of this disease.

Where are we now in treating breast cancer?Through epidemiological studies, we have a better understanding of the main risk factors for breast cancer, whether it be age and reproductive factors that influence exposure to the hormone, estrogen, and were learning a lot more about genetic risk for breast cancer.

Back in the mid-1990s it was all about BRCA1 and BRCA2 mutations but now, in the past several years, were testing for multiple genes that can predispose to breast cancer as well as other cancers. And with next generation sequencing, were able to sequence the whole genome much more cheaply and much more quickly. This has led to an increase in our understanding about genetic susceptibility to breast cancer in particular.

Once a person knows about her genetic risk factors or that they are predisposed to breast cancer, what then?We know if a woman has a genetic predisposition, she has the option for enhanced screening, with not just mammography, but more sensitive screening tests like breast MRI. If she has a high penetrance gene she may opt for prophylactic mastectomy. Certainly when Angelina Jolie wrote her Op-Ed in The New York Times about getting a bilateral mastectomy after she found out she had a BRCA1 mutation that really helped to increase awareness.

Now that were finding these more moderate risk genes it has becoming harder to know where to draw the line. We dont want women to do unnecessary surgery or to do unnecessary procedures because that may be potentially harmful. I think were still learning what to do with that information. Knowing more about a persons genetic risk has definitely helped to make breast cancer risk much more personalized and we are always trying to provide the right intervention for the right level of risk, per individual.

There are many types of breast cancer. Can you give us the lay of the land of the main subtypes?The different subtypes of breast cancer all behave differently and we treat them differently. The most common is the estrogen receptor positive breast cancer, which counts for about 70% of all breast cancers and we know that these types of breast cancers respond very well to anti-estrogen therapy. More recently weve been using a class of drugs called aromatase inhibitors in post-menopausal women. In many ways thats been one of the most effective targeted treatments that weve had for breast cancer we can see up to a 50% to 65% relative risk reduction in breast cancer relapse with these drugs.

There is HER2-positive breast cancer and recently, theres been an explosion of new drugs for treating this subtype. Within just the past few years, at least four or five additional drugs have been approved for HER2-positive breast cancer. Although it is a more aggressive form of breast cancer, it is also a type of breast cancer that responds well and is very sensitive in general to chemotherapy and targeted therapy. Even in patients who have metastatic disease, women are living longersometimes for more than five yearswith advanced breast cancer.

The most challenging type of breast cancer to treat is triple negative breast cancer, meaning that it is negative for the two hormone receptors estrogen and progesteroneand also negative for the HER2 receptor. We cant treat it with anti-estrogen therapy and we cant treat it with any HER2 targeted therapies. In this case the main treatment option is chemotherapy, which has its own set of side effects associated with it.

Is this a focused area of research right now?Yes, its an area very ripe for new discovery and research. Recently there was drug approval for immunotherapy for triple negative breast cancer, particularly in combination with chemotherapy. Immunotherapy is a very new type of therapy thats gotten a lot of attention in the press and in the oncology world.

Tell us how immunotherapy could impact breast cancer.Currently, immunotherapy is approved in patients with metastatic triple negative breast cancer but there are a lot of clinical trials that are looking to expand the use of this medication for other breast cancer subtypes. Typically in cancer in general we test these new drugs in patients with advanced cancer who have fewer treatment options and in those cases we may only prolong their survival by a few months. Its much more exciting when we can then take these drugs, if theyre found to be safe in patients with early stage disease, to see if we can improve cure rates. There are ongoing trials testing immunotherapy in patients with early-stage breast cancer, especially if they have high risk disease, to see if we can prevent a relapse and therefore cure them.

What are the other exciting areas of breast cancer research right now?A big trend within oncology and within breast cancer in particular is the de-escalation of therapy. Can we spare some patients from unnecessary treatment? We dont want to over treat breast cancer. We want to treat the high-risk patients but the ones with a more favorable breast cancer, we want to spare them some of the side effects of chemotherapy, for example.

One major breakthrough is as we understand the biology of these tumors a little bit better, we can better classify patients. There are different molecular tumor tests we can use now, including Oncotype Dx, MammaPrint, breast cancer index all of these new tumor tests gives us the opportunity to personalize a womans breast cancer care. Based upon a womans tumor biology, we can assess who needs chemotherapy, who may benefit from extended hormonal therapy, who can do well with just five years of anti-estrogen therapy, and then we can spare them from a lot of the side effects that weve seen from some of these drugs. I think that de-escalation of care has helped cut costs and certainly reduces long-term side effects in our breast cancer patients. We dont want to keep adding on expensive treatments on patients who dont necessarily need it.

You run the High-Risk Prevention Clinic. Whats new in prevention?Similar to the breast cancer treatment field, in the preventive setting you have to look at this not as a one-size-fits-all for women. We can now better refine what a womans risk is and give individualized guidelines for them. Prevention is getting more complex. We dont just test for BRCA1 and BRCA2 genes; there are multi-gene panels that we can test for. Now theres a lot of interest in polygenic risk scores (PGS), so rather than looking at one gene we can look at a bunch of genetic variants sometimes hundreds of genetic variations and come up with a risk score based upon those hundreds of variants. Based upon that score, we place women on a spectrum of risk and then use that to make recommendations about screening, lifestyle modifications, preventive surgeries, and even medications. For example, anti-estrogen drugs have also been shown to be effective in the prevention setting.

How has screening for breast cancer evolved or changed?There are major advances on the screening front as well. For a long time we mainly only had 2D digital mammography and now we have 3D mammography, or tomosynthesis. Rather than just having two views of the breast you can have serial slices of the breast and that can help to increase the sensitivity of the mammogram, particularly in women who have dense breast tissue because having dense tissue can lower the sensitivity of the mammogram for early detection.

There is actually a lot of controversy around screening. Just as we know there are more than one type of breast cancer and more than one level of risk, were trying to adopt less of this sort of one-size-fits-all for breast cancer screening. For instance, not all women need to get yearly mammograms, maybe just higher risk women with dense breast tissue could get enhanced screening with either ultrasound or MRI. But for the majority of women who are not high risk, perhaps we can think about cutting back on mammography screenings. Current guidelines are that if you are average risk you can wait until youre 50 to get mammograms every two years, rather than yearly. Maybe less frequent screenings can also reduce some of the harms of screenings, like increased biopsies.

What does the future hold for breast cancer research and treatment?All of the new drugs and targeted therapies have definitely incrementally advanced the field.

The most exciting is this idea of precision medicine, both for prevention and for treatment, and using genetic information to assess breast cancer risk, having the genetic information of the tumor tissue to assess the aggressiveness of the cancer and being able to tailor treatments specific for individual patients is what we are working towards. I think that more than anything else having that genetic information tailoring our carehas really put more tools in our tool box in terms of what we can offer patients.

-Interview by Melanie A. Farmer

Related:Five Questions with Dr. Eileen Connolly: 'Less is More' Adage Signifies Shift in Breast Cancer Radiotherapy

Read the rest here:
Q+A: Katherine Crew, MD, on the Many Advances in Breast Cancer and What's to Come - Columbia University Irving Medical Center

Recommendation and review posted by Bethany Smith

This article is the part of a monthly series of stories focused on cancer issues. Denver7 is proud to partner with the American Cancer Society, Cancer Support Community, Colorado Cancer Coalition and Sarah Cannon Cancer Institute at HealthONE to bring you these stories, tips and resources.

DENVER -- This year, the American Cancer Society estimates that 4,530 women in Colorado will be diagnosed with breast cancer in 2020 and 640 women will die from the disease.

Breast cancer screening is important and can detect the disease when symptoms appear, or before there are any signs. The following American Cancer Society guidelines are for women at average risk:

For more information on screening and risk factors, visit https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html

If a patient had to reschedule their screening in the midst of the pandemic or are due for their screening, they should talk to their healthcare team. Providers can discuss balancing the risks and benefits of being screened now or postponing for a later date, considering personal and family history, other risk factors, and the timing of the last screening test.

Signs and SymptomsIts important to know how breasts normally feel and to be aware of any changes. A common symptom is a new lump or mass, but other things to be aware of include:

If you notice any changes, contact your doctor. For details visit https://www.cancer.org/cancer/breast-cancer/about/breast-cancer-signs-and-symptoms.html

Mammogram Q&AI'm pregnant or breast-feeding and due for a test. Should I wait?

I have a breast implant. Can I still get a mammogram?

What else should I know?

Continued here:
What you need to know about breast cancer and screenings - The Denver Channel

Recommendation and review posted by Bethany Smith

Ginger is a plant that has been used to treat ailments for thousands of years. Not only is ginger a delicious addition to cooking because of its spicy and unique flavor, but it's also great for your health.

Here are six health benefits of ginger and how to add it to your diet.

A small 2017 study tested the antioxidant effects of ginger in cancer patients receiving chemotherapy. Those who received a daily ginger extract had higher levels of antioxidants and lower levels of oxidative stress than the placebo group.

Advertisement

Typically, inflammation goes away once your body repairs itself. But, when you're experiencing oxidative stress, it can cause chronic inflammation. This causes your body to damage healthy cells, tissues, and organs. Chronic inflammation may lead to diseases like heart attacks or chronic pain like arthritis.

Ginger contains a compound called gingerol. Gingerol is known for improving gastric motility the passage of food through the body and suppressing muscle spasms. This can help settle the stomach and reduce symptoms of nausea and vomiting.

Ginger is also a safe and effective herbal remedy for pregnant women with morning sickness. A small 2009 study tested the effectiveness of ginger capsules on pregnant women experiencing nausea and vomiting. Pregnant women who took four 250mg ginger capsules daily for four days experienced less nausea and less vomiting than women who received a placebo.

In a 2015 study, scientists reviewed previous research looking at the effects of ginger on menstrual pains and concluded that 750 to 2000mg of ginger powder can help relieve pain during the first three to four days of the menstrual cycle.

There is also some evidence to suggest ginger can help control blood sugar levels in people with diabetes by increasing glucose uptake in muscle cells without insulin.

Ginger stimulates digestive enzymes responsible for moving food through the body more quickly, which prevents gas. "[It] helps the body break down gas and get rid of gas more effectively," Ankewe says.

According to Anekwe, you can easily incorporate ginger into your diet by:

See the original post:
6 science-backed health benefits of ginger and how to add it to your diet - Business Insider India

Recommendation and review posted by Bethany Smith

Youre powering through your day like a boss. A Zoom meeting here, a report thereyup, youre feeling unstoppable. Nothing can bring you down. That is, until its 4 p.m., and all of a sudden, you want to take a nap. You wonder where your energy has disappeared to as you slog through email after email, wishing that quitting time wasnt a whole hour away.

If youve experienced this phenomenon, youre far from alone.Several studies have confirmed the so-called afternoon slump, including one from The National Sleep Foundation that pointed a sharp drop in circadian rhythm that plummets between 2 and 5 p.m. every day.

Tiredness is a fact of life, no matter what time of day it is. Max Kerr DDS, D-ABDSM, a dental sleep expert with Sleep Better Austin, emphasizes that its extremely common for people to feel tired, even if it goes beyond the afternoon slump.

First, give yourself a break, he says. Life is tough. We have a million commitments and not enough time. Relax and take care of yourself. You have to make your health a priority, because no one else will.

Dr. Kerr adds that although its normal to feel tired, you dont have to keep pushing through that afternoon fatigue when there are options available to you. He advises, Seek out a sleep coach, ask your primary care physician for a Home Sleep Test, get your blood tested, and give yourself the gift of purposeful movement. Conquering fatigue can open up life and joy in a most profound way as well as positively impact everyone around you.

It can also help to know why you face afternoon tiredness each and every day. Here, three medical experts address the question: Why am I always so tired in the afternoon? Here are 13 possible reasons why.

Dr. Ilene Ruhoy, MD & PhD, and Gut Council Member for the probiotics company Jetson, believes that our energy states greatly depend upon our hormone levels, such as glucocorticoids, leptin, melatonin, and more, she says. These hormones can be impacted by our sleep and eating habits.

Dr. Ruhoy explains, In the mid-afternoon, levels of these hormones are low. However, the absolute levels and the control of secretory rhythms can be influenced by meal and sleep patterns. Sleep fragmentation, poor sleep hygiene, and sleep deprivation all contribute to the feeling of fatigue in the mid-afternoon when hormones are low.

If you suffer from depression, you know how hard it can be to get out of bed some mornings. Pushing yourself through the day can naturally make you feel depression-related fatigue in the afternoon. The insomnia you experience from depression can also cause you to lag mid-day.

Dr. Abe Malkin, M.D. M.B.A. of Concierge MD LA says, Studies have shown that 75% of people suffering from depression show symptoms of insomnia while the other 25% suffer from hypersomnia, which is excessive daytime sleepiness.

Many of us simply forget to drink water throughout the day if we dont make it a priority. All those meetings and phone calls can push hydration way down on your to-do list, but if you want to beat that afternoon slump, drinking up is key.

Water is the main component of our bodys structure, Dr. Kerr notes. When we are habitually dehydrated, it can affect the normal functioning of our body. The harder our body has to work for its normal functioning, the more energy is needed. The less efficient we are, the more tired and fatigued we become.

In other words, regularly sipping that H2O might even make you more productive.

Related: Can You Drink Too Much Water?

Dr. Ruhoy details, Excessive food consumption, sugar and processed food intake, and poor eating habits, such as eating too many meals, doing stressful eating, or doing hurried eating, contribute to fatigue. Minimize or eliminate sugar and processed foods. These foods contain substances that promote inflammation and can disrupt the hormonal balances that impair our rhythms.

She says that in simpler terms, the post-sugar crash is a real thing. You may want to rethink that 2 p.m. doughnut if you want to stay energized through the afternoon.

In addition to what youre eating, it also comes down to when youre eating. Lunch in the middle of the day could be contributing to your lethargy, and you may need to tweak your mealtimes.

Leptin levels, the hormone that suppresses hunger, is low at noon and lowest at approximately 4 p.m. of our 24-hour cycle. Meals in the morning and early evening, over time, will help the daytime fatigue. Studies have shown fasting improves energy state and it may be that it is not truly fasting at all but rather a more natural meal pattern, Dr. Ruhoy states.

If youre someone who feels anxious as soon as your alarm goes off, its no wonder that you feel depleted in the afternoon.

Dr. Malkin says, A chronic anxiety sufferer will still feel exhausted even after a full nights rest because of constant fear when there is no real danger. It is best to schedule an appointment with your doctor to help pinpoint the issue and get treatment to help combat the anxiety.

Related: What Is Social Anxiety?

Our body uses sugar for energy, Dr. Kerr says. The carbohydrates that we eat are converted to glycogen and transported throughout our body in our blood. Insulin will move the sugar from our blood to the cells that need it. If our insulin metabolism is off, which can be caused by diabetes, then our blood sugar can be too low or too high. This can impact the sugar available to our nervous system in order for it to function appropriately. When this happens, we will become very fatigued and sometimes very disoriented. Insulin metabolism is negatively impacted by poor diet and poor sleep.

Heres some major motivation to get your sweat on: exercise just might eliminate your afternoon slump altogether. Exercising regularly can help combat fatigue, Dr. Ruhoy says. Exercise promotes mitochondrial efficacy and it does not require triathlons or climbing Mount Everest. Daily movement helps maintain systemic blood flow and natural levels of adrenal and hypothalamic hormones throughout the day.

Book a morning spin class, sneak in a lunchtime run, or do some calming-yet-calorie-burning yoga at the end of the day.

Related: Best Workout Apps 2020

Dr. Ruhoy explains that sunlight is a huge component of setting proper circadian rhythm, the biological process that regulates our sleep-wake cycles. That means that your body is craving a noon walk in the sunshineor even better, get out to walk in the sun as soon as you wake up.

She says, We often focus on sleep, which is important to be sure, but part of that cycle includes wake, which is one reason why regular meal patterns can be crucial. But getting outdoors each day is important to simulate that rhythm. It does not have to be a sunny day as all that is needed is natural light.

If youre a coffee-drinker, youre likely already aware that if you guzzle a few cups in the morning, it could result in an afternoon crash fueled by a lack of java. And according to Dr. Malkin, the pandemic has been marked by an increase in caffeine all around.

The standard morning cup of coffee became morning, afternoon, and evening joe to help us stay up for Netflix binges and try to function during a Zoom call the next day, he says. Im all for a shot of espresso, but in moderation. When taken in excess, [caffeine] will quickly give you the ultimate jolt but remember what goes up must come down.

To pace yourself, he says that a good rule of thumb is to drink a glass of water equal to your cup of coffee or other caffeinated beverage.

When you find yourself with a few free minutes during the day, were guessing that youre scrolling through social media. Although this can provide an entertaining, or even mindless, diversion, it could result in exhaustion later. Too much screen time isnt good for anyone, Dr. Malkin says. Our brains are actively working to absorb all the images, but lets not forget that the brain is the bodys command center. It gives out all the instructions for when its time to eat, sleep, or work. This is our personal computer which also needs time to reboot just like an athletes body after a rigorous workout.

There are some health conditions that can lead to overall fatigue, the afternoon slump included, and one of those disorders is narcolepsy.

Dr. Kerr says, Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. People with narcolepsy often find it difficult to stay awake for long periods of time, regardless of the circumstances. Narcolepsy can cause serious disruptions in your daily routine.

If you suspect that you may have narcolepsy, its a good idea to schedule an appointment with your doctor.

Stress is a natural, albeit less-than-desirable, part of everyones lives. And needless to say, for many reasons, stress has become even more rampant during the pandemic. When youre stressed out, it can definitely take its toll on your daily energy level.

Celebrity interviews, recipes and health tips delivered to yourinbox.

Dr. Ruhoy shares, Emotional, physical, and mental stress can wear us down and make us less motivated to accomplish tasks or engage in social activities, and over time, the effects of stress can fatigue our cells. Stress has real physiologic effects that can ultimately cause fatigue.

Next up, find out if weighted blanket really help with insomnia.

Excerpt from:
Why Am I So Tired In The Afternoon? 13 Reasons Why - Parade

Recommendation and review posted by Bethany Smith

The president has had a life-threatening, infectious disease for over a week, and he and his doctors havent been very transparent about the timeline and course of his affliction. In lieu of detailed disclosures, reporters have to piece together his condition based on the treatments hes been receiving.

Trump was started off on an experimental therapeutic an antibody cocktail and then advanced to another remdesivir. The other biomolecules coursing through Donald Trump's system (and this week's headlines) are corticosteroids, called dexamethasone.

You may have heard of cytokine storms, where the body's immune response to severe COVID-19 bombards healthy cells, making the illness worse. Trump has been given dexamethasone, an immuno-supressant that doctors prescribe to temper that effect. Unlike the other experimental treatments, dexamethasone is common and somewhat easy to access. However, it is rarely administered to a patient with a case as (self-)reportedly mild as Donald Trumps. In an interview with New York Magazine's Intelligencer, the co-author of a recent study testing dexamethasone elaborates:

That lack of evidence is concerning as Trump heads into a critical point in the course of his illness. COVID-19 is known for being a bit of a roller coaster, with intermittent fevers, mysterious symptoms, and rapid declines. Abraar Karan, a physician with experience treating patients with COVID-19, told Monique Brouillette at Scientific American that some people have turned corners and left the hospital, only to come back feeling much sicker, with even worse oxygen levels and possibly other harm to the bodys organs.

It is theoretically possible that the early steroid treatment may ward off a dangerous auto-inflammatory reaction. But beyond the inherent risks of immuno-supression, corticosteroids may also cause behavioral side effects in the President. Trump's cognitive and behavioral state has been a point of concern for years. Potent steroids such as dexamethasone are known to increase appetite, decrease restful sleep, and bring about heightened "maniacal" energy states.

As the nation enters the weekend, Speaker of the House Nancy Pelosi is rolling out a 25th amendment commission, Trump is boasting a miraculous recovery with a Fox News doctor, and the rest of us continue to wait and learn how biology will run its course. For better or worse, the side effects our president experiences may prove to have historical consequences. To my knowledge, roid rage has never been a factor in nuclear geopolitics.

View original post here:
A tiny particle collider yields new evidence for a type of 'quasiparticles' called anyons - Massive Science

Recommendation and review posted by Bethany Smith

Beta blockers are often prescribed for high blood pressure, especially if the patient has suffered a heart attack. A new study shows they may not be as effective as once thought.

The study was done in Italy at the University of Bologna. According to researchers, it appears that these beta blockers may not be as effective in women patients as they are in men. Data indicated that women had a higher rate of heart failure than men when they had angina or a heart attack.

The study had 14,000 participants from 12 different countries in Europe. Each one had a diagnosis of high blood pressure, but none of them had a heart disease diagnosis. According to the research, women may have an almost five percent higher risk for having heart failure after a heart attack when taking beta blockers. For those who didnt take the medications, the rate of heart failure was about the same for both men and women.

Researchers dont know the cause for this possible difference. One theory is in the interaction between the beta blockers and hormone replacement therapy. It is obvious that more research focused on women is needed. According to doctors and scientists, research often leads to blanket statements that may not hold true for both men and women.

Women present differently with heart issues than men. They also have a unique physiology from men, which leads to the idea that they may react differently to the same medications as men. Other researchers say that beta blockers pose a risk for anyone, whether the patient is a man or woman.

Beta blockers do their work by blocking the transmission of the hormone epinephrine, which is better recognized as adrenaline. These medications slow down your heart rate as well as the force with which it beats. The result is that your blood pressure is also lowered.

The medications have a secondary job which is to open up the veins and arteries for better blood flow. Not all beta blockers work the same. Some focus on the heart rate while others also impact the blood flow. Some popular brand names of beta blockers include Sectral, Corgard, Zebeta, Toprol XL, Tenormin and Inderal.

Beta blockers arent usually the first line of defense against high blood pressure. Diuretics are often prescribed first. Beta blockers may be prescribed if other medications arent effective and with other drugs designed to lower blood pressure.

Doctors may prescribe these medications for angina, heart attacks, irregular heart rhythm, and migraines. They are often given with other medications.

Beta blockers arent usually recommended for people with asthma because it may trigger an attack. It is also not the first choice for people with diabetes because it can mask signs of low blood sugar.

Until more research is done, it is important to discuss medications like beta blockers with your physician and to tell them everything about your medical history to ensure it is the right choice for your health condition.

Read the original:
Senate Bill May Give More Authority to the FDA for Drug Recall - Med News 365

Recommendation and review posted by Bethany Smith

Katie Byard| For the Akron Beacon Journal

Weve got big news about this little root beer stand that has persevered.

For this first time in its 67 years, the B&K Root Beer drive-in in Cuyahoga Falls, a neighborhood staple, will stay open all year. Previously each year since 1953 the stand closed in the fall.

Loyal customers who in years past have stocked up on pints and quarts of coney dog sauce for the winter are rejoicing.

Weve weathered the storm. Alot of these smaller businesses have not made it," through the COVID-19 pandemic, said Scott Reynolds, who, along with his wife, Christy, owns the old school place at 737 Munroe Falls Ave.

The Reynolds purchased the business in 2015, becoming independent operators of the B&K that years ago was part of the long disbanded B&K drive-in chain.

This has been our best year ever, Reynolds said, noting he wants to keep the momentum going. Weve been very fortunate with all our loyal customers and new ones that discovered the places coney (Spanish) dogs, kraut dogs, hamburgers that are made fresh upon ordering, soft-serve ice cream and more.

I can walk here if the weather gets too bad, said customer Larry Dean, 79, who became a regular about four months ago, after moving nearby to the stand, tucked in a neighborhood.

Last week, Dean, a retired warehouse and inventory manager, drove to the B&K to pick up lunch for himself and his wife. He got his regular order: one coney dog ($2.40), one kraut dog ($2.40), a hamburger ($2.80) and fries ($1.65 for a small order; $2.25 for a large).

Americans are craving more comfort foods during the pandemic, food industry officials say, and the B&K offers familiar eats.

Familiar but upgraded Reynolds says.

Since taking over in 2015, Reynolds, 45, and his wife have kept the vintage vibe freshening up the familiar orange and brown paint while making changes.

The stand now serves one-third pound burgers (larger than before the Reynolds took over) that are formed with the hamburger press that Christy Reynolds grandmother used.

Buns are from Lakemore's Ideal Bakery.

They stand up to our burgers, Scott Reynoldssaid.

Hamburgers previously only offered on Tuesdays are now on the daily menu.

Also joining the daily menu is soft-serve ice cream. One flavor is offered each week.

I am happy to report I have added the B&K to my list of fave area burger places. I brought a couple of cheeseburgers home (including one with grilled onions) for my hubby and me to eat. The stands burgers are straightforward and filling. And, yes, I enjoyed the bun that melded nicely with the cheese and meat, but did hold up.

We also enjoyed a kraut dog (a hotdog topped with homemade sauerkraut that has a sweet flavor), a coneydog (topped with homemade coney sauce) and french fries.

Sides including french fries, tater tots, onion rings, mozzarella cheese sticks are now deep fried. Previously, they were cooked using an air method without grease. Reynolds said customers wanted that classic fried taste.

The stands side of sauerkraut balls isfrom Akron-based Ascot Foods, with roots in the formerBunny B Sauerkraut Balls & Ice Co.

It was rough for the first few years after the couple bought the stand in 2015, Reynolds said.

He noted the business finances were stretched with the purchase of new equipment, including new freezers and refrigerators.

We didnt really know what we were doing at first, he said.

Reynolds, a maintenance supervisor at the Ford Motor Co. plant in Brook Park, and his wife, Christy, a nurse, were looking for an investment when Christy spotted an advertisement saying the stand was for sale.

The idea of running a family business appealed to them. Their children Scott, a fireman;Brian; and Madison, a college student, all work at the stand.

Brians availability to work full-time at the stand now is helping to drive the decision to stay open all year.

The stand is one of three independently operated B&Ks in the area.

Initially the stands were part of the B&Kchain, which began in Michigan City, Ind., in the 1940s. B&Kstands for Bergerson & Kenefick.

Sheila Trombka, a part-time cook at the Cuyahoga Falls stand, is a daughter of Al and Cathy Emich, who acquired the stand in 1958 and sold it in 1996 toVic and Dixie Davis, who sold the stand to Scott and Christy Reynolds in 2015.

Trombka has worked at the stand for virtually her whole life. She learned to wash root beer mugs when she was 5 years old and when she was 9, she ran the register. By the time she was 11,she was a carhop. Now her sons, James, 22, and Jonathan, 18, work part-time there.

She showed us the ropes. We love her to death, Scott Reynolds said.

I came with the building, Trombka said.

About B&K in Cuyahoga Falls

Address: 737 Munroe Falls Ave.

Hours: 11 a.m. to 8:30 pm. Tuesday through Saturday - now, all year.

Phone: 330-922-3355

See the stands Facebook page for specials.

New downtown eatery

Evelyns Coffee & BnhMi has opened at11 E. Exchange St., inthe space behind the Goodwill blue boutique on Main Street in downtown Akron.

The space previously housed coffee shops, including Wholly Joe.

So what is a bnh mi?

Bnh mi is the Vietnamese word for bread, and also in this case refers to the popular Vietnamese baguette sandwich (think sub sandwich on crusty, light bread), typically featuring a meat and pickled vegetables.

French colonists introduced the baguette to Vietnam, but the Vietnamese have made the sandwich their own, creating many versions.

At Evelyns, I enjoyed a chicken bnh that included pickled carrots, cucumber and cilantro ($5.50). You can also get a beef or meatball bnhmi.

Eveylyns also offers kimbap, a Korean dishof seasoned rice with fish cakes, carrots, egg and spinach rolled in seaweed. Other offerings include smoothies, papaya salad and a Vietnamese salad made with shredded cabbage, chicken, carrots and onion. It comes with a sweet and tangy dressing.

The shop offers Vietnamese iced coffee (made with sweetened condensed milk), along with a variety of other coffee drinks.

Vinh Nguyen, a local physician, opened the place this summer, taking advantage of the Start Downtown program operated by the nonprofit Downtown Akron Partnership. The program provides six months of support, including rent subsidies, in the 42-bock Special Improvement District in downtown Akron.

Evelyns is open from 8 a.m. to 4 p.m. Monday through Friday and 9 a.m. to 4 p.m. Saturday.

Phone is 330-849-5080.

See Evelyns web page --https://www.evelynscoffee.comfor more information and to order online.

West Side Bakery's Apple Week

This week is Apple Week at the West Side Bakery in Akron, celebrating 25 years in business this year.

Barb Talevich, who owns the bakery with her husband, Steve, said she expects to go through some fiveor six bushels of Golden Delicious apples from Bauman Orchards in Rittman to make a variety of apple treats.

Available now: Apple cobbler, apple hand pies, caramel apples, apple cobbler tea bread, apple coffee cake, cinnamon apple cheesecake and apple-frangipane galette (an apple tart featuring an almond pastry cream).

Apple fritters will be available this Friday and Saturday.

Its the only time of the year these fried treats are available.

Talevich happily reported that the bakerys employment roster is now back up to more than 20 full- and part-time workers.

For a time during the ongoing pandemic, she and and her husband were the only workers, and the shop was only open on Saturdays.

The shop, at 2303 W. Market St., is now open from 8 a.m. to 5 p.m. Monday through Saturday pickup only. Phone is 330-836-4101.

ThaiSoul Fusion Grill relocates

ThaiSoul Fusion Grill has moved to 992 Kenmore Boulevard in Akrons Kenmore neighborhood.

Thats the space that previously housed Lil Bit Cafe, which closed earlier this year. It apparently was not able to withstand the negative financial impact of the ongoing pandemic.

Well have more soon on ThaiSoul Fusion Grill, which, as its name suggests,offers Thai eats, as well as soul food.

Owners are Tawon and Patricia Burton. They most recently operated the eatery in Stark County, after running it out of space on Romig Roadnear the site of the former Rolling Acres Mall.

Phone is 330-937-8846. Online ordering is athttps://www.thaisoulfusiongrill.com.

The restaurant is only open for pickup at this time.

Wise Guys' clambake

Wise Guys Lounge & Grill in Akrons North Hill will offer a clambake from 3 to 9 p.m. Friday and Saturday.

Cost is $55 for clams, mussels, crab legs, potato, a half check, corn and clam chowder.

Add lobster for $10.

Guys, known for its wide selectionof wine, is at 1008 N. Main St. Phone is 330-922-3006.

Harvest Mart at Lock 3

Harvest Mart featuring food and non-edible items will debut at Lock 3 park off Main Street in downtown Akron on Saturday.

Itll run from 1 to 5 p.m. Saturday, and from 1 to 5 p.m. Oct. 24.

See the Harvest Mart at Lock 3 Facebook page for more information.

Akron'sJ Hudson, an experienced organizer of markets, is coordinating the event.

Hormone-free chicken, turkey, pork, lamb and beef, as well as pumpkins, gourds, apples, late-summer produce and more,will be available.

Cast your vote for favorite burger

You can vote for your favorite burger among two choices at Bob's Hamburg in Akron.

In its "Keeping Burgers Great 2020" election, you vote by buying the quarter pound burger with Swiss cheese and jalapenos or the burger with American cheese, ketchup, onions and mustard. A portion of each saleeach burger costs $6.35 will go to Akron Children's Hospital.

Voting continues through Nov 2. The winner will be revealed Election Day, Nov.3.

Bob's is at 1351 East Ave., near Interstate 76.

Last call at Louie's

As reported by Beacon Journal staff writer Alan Ashworth last week, Louie's Bar & Grille at 739 E. Glenwood Ave. in Akron's North Hill is closing this month. The 28-year-old Louie's, known for its burgers, cited COVID-19 restrictions in its decision to close.

Last day for customers is Saturday.

Thanks for the memories.

Send your local food news to Katie Byard at msakron@sbcglobal.net.

Read more from the original source:
Akron Dish: For first time, B&K drive-in staying open through winter in Cuyahoga Falls - Akron Beacon Journal

Recommendation and review posted by Bethany Smith

Monday, October 12, 2020

Dr. Michael Fine, Author

View Larger +

Justice Brett Kavanaugh

The full audiobook can be downloaded here.

"Boys and girls like beer"

-- Brett Kavanaugh, Associate Justice, US Supreme Court

Every morning at 5 AM, three or four white minivans leave from a parking lot on Cowden Street in Central Falls, Rhode Island for factories all across southern New England. Each minivan is densely packed with 10 to 15 mostly undocumented immigrants who live two or three or five people to a room in the ramshackle wooden frame triple-deckers that are crammed into every available square foot in this old mill city. The people in the minivans are from all over the world - from Guatemala, Honduras and El Salvador, from Cape Verde, the Dominican Republic, Colombia; and Puerto Rico refugees from Hurricanes Maria and Dorian who cant find other jobs here. The vans are run by labor contractors who find and supply unskilled labor to the low-wage employers who need bodies for the hot, dirty, smelly and dangerous jobs no one else wants, in the factories, construction sites, meat-packing plants and fish-houses of Southern New England. The vans charge each worker $5 to $10 a day. The work pays minimum wage - $10.50 an hour in Rhode Island, $12.00 an hour in Massachusetts, $11.00 an hour in Connecticut. Theres lots of wage theft on these jobs sometimes workers only get paid for eight hours when they work 12 or 14, or get told the labor contractors havent been paid yet and then never get paid, or are paid piece work using a scale that means they earn $5 or $6 dollars an hour, when they were promised $20 an hour but youd have to produce at an impossible pace to generate that much income.

Yes, we drank beer. My friends and I. Boys and girls. Yes, we drank beer. I liked beer. Still like beer. We drank beer, said Judge Brett Kavanaugh during his testimony to the US Senate Judiciary Committee confirmation hearing.

This testimony provided a unique lens on American culture and mores. A preening conservative President, pandering to his base, chose an undistinguished juror to sit on the U.S. Supreme Court. The opposition party, powerless to stop Kavanaughs confirmation, used accusations about the nominees behavior in high school as the bulwark of their objections to his nomination.

By the time Judge Kavanaugh testified, the process of Supreme Court nomination and confirmation had already been defiled. The nomination to the Supreme Court of Judge Merrick Garland two years earlier had been blocked by the Senate Majority leader, just because he had the power to do that. This occurred just six years after a President had forced through health care insurance reform, because he had the power to do that. Health care insurance reform was unanimously opposed by a minority party, even though the reform itself was based on the ideas of that minority party, which objected only because it was in their perceived political interest to resist the reform, the hell with what the country wanted and needed.

Any pretense of government of, by and for the people, and of governing for the good of the nation had fallen by the wayside years ago. The U.S. Government has long been controlled by special interests, the consequence of the over-centralization of capital, itself a consequence of changes in banking and securities regulations that had been sought by the banking and securities industries themselves. The notion of a common good, of Americans as one people with liberty and justice for all was replaced by narcissism, consumer capitalism, and greed. Brett Kavanaugh is a shallow self-satisfied man - the pure product of a culture without compass or meaning. He now sits on our highest court, appointed for life. I worked hard, he said. I played basketball. I got into Yale and Yale Law School. I got ahead. And yes, I like beer.

These are the values we brought with us into a pandemic.

The nomination and confirmation of Brett Kavanaugh posed a simple question. In the words of another time - have we no sense of decency or responsibility to ourselves as a people?

The story of SARS-CoV-2 and of Covid-19 makes the answer to that question clear. We let loose a pandemic in the US that will cost at least 250,000 lives because we have lost our sense of dignity, our discipline, our courage and our pride.

Almost all the deaths from Covid-19 were preventable. Any fingers to be pointed must be pointed directly at us at ourselves, our culture and our politics. No one did this to us. We did this to ourselves.

Sometime in September or October of 2019, a bat, a pangolin or some other wild animal in China coughed, sneezed, or cried out, perhaps in pain from being caught or slaughtered, or just breathed near a human being. Out of that animal came a virus or more likely a thousand or more viral particles from the family of viruses called Coronavirus - that hung in the air for a moment. Then a human being nearby inhaled. The virus entered the nasal passages and perhaps the lungs of that person, an event likely happens millions or even billions of times a day.

The transfer of viral particles from animals and other human beings is a common, even trivial, event in the human experience. Those particles are always in the air we breathe and they are what our nasal passages, our lungs, our respiratory secretions and our immune systems work to protect us against almost always effectively. Most of the billions of viral particles we inhale or introduce into the body by touching eyes, nose or mouth have no significant impact on the health of individuals. Many viral particles that infect other species plant viruses, insect viruses, frog and toad viruses and bird viruses - have cellular architecture that is slightly different from the cellular architecture of human cells, so most of those viruses are unable to attach to human cells or cause infection. Most of those viral particles are quickly destroyed by the immune system. Most are just dust.

But the virus that entered a human body in the fall of 2019 was different. That virus, which likely evolved in another mammal, had a mechanism that allowed it to attach to specific proteins in certain human cells, cells that line the nose, are present in the lungs and heart and in small numbers in the gastrointestinal system, proteins that are called ACE2 receptors. ACE2 receptors are the proteins that allow the attachment of a hormone called angiotensin converting enzyme, a hormone that helps regulate blood pressure, among other functions.

The virus attached to human cells. It entered those cells and inserted itself into the genetic material of those cells, which is what viruses do. The virus then caused those cells to make copies of itself. Those copies destroyed the cell and were released into the bloodstream where they found and attached themselves to the ACE2 receptors of other cells and entered those cells and their genetic material. Those cells began making still more copies of the virus billions and billions of copies.

That human being had become infected. And then that human began to cough, or sneeze, or breathe or speak, so that the virus entered the air and infected other people nearby. And those people coughed and sneezed and infected other people. The newly infected people infected others, over and over again, until at least sixteen million people who have been tested and counted, as I am writing this, but very likely many more than that likely a hundred to two hundred million people - people who have had the virus but havent been tested or counted have become infected. Which is not many, really, when you consider that none of us has seen this virus before so have no immunity to it. And that there are seven billion of us. Likely all seven billion human beings are susceptible to this new virus and will become infected with it before long since none of us were immune to it in the fall of 2019.

Seven billion humans. 200 million people is about three percent of seven billion, so many more people will become infected before this pandemic is over.

I thought Id sit out the Coronavirus outbreak in the US as an observer. Im a fiction writer turned doctor turned fiction writer again. I worked as a family physician and then started doing public health in my late fifties. I was Director of the Rhode Island Department of Health 2011-2015 a period that included the Ebola epidemic of 2014-2015. Along the way Ive had the privilege of knowing three CDC directors, three Surgeons General (one of whom I helped train to be a state health officer, in 2015) and about 100 city and state health directors, a number of whom are close and dear personal friends with whom I talk frequently. I know CDC and its culture. Many friends and colleagues work there. And I also know government and how it works at the federal, state and city levels. Or doesnt.

When reports began to come out of China of hospitals overwhelmed, of a doctor who had been silenced and then died of the disease, of health workers getting sick and dying in large numbers, of people dying in the streets of Wuhan, I was writing in the morning, and working in the afternoons seeing patients two half days a week, and trying to develop new programs to reduce cost and improve access to health services in Central Falls, Rhode Island, the smallest, poorest and most densely populated city in the state. I consulted a little with the mayors of Central Falls and Pawtucket, Rhode Island, a neighboring city, but had turned my attention to writing fiction, an old first love. I worried a little about this new virus but I assumed that the Chinese CDC and WHO would get in front of it and get it stopped before it spread too far.

I didnt expect to find myself in the middle of one of the worst outbreaks of Coronavirus in the nation.

I also didnt expect the public health apparatus of the world and nation to so dismally fail. Or that the failure would reveal again what my 2018 book Health Care Revolt was written to reveal originally that we have a medical services market, a pharmaceutical products market and a health care insurance market but that we dont have a health-care system in the United States, a system that provides the same set of essential services to all Americans. Our medical, pharmaceutical and health care insurance markets are focused on profit, as markets should be, and not public health. These markets, and the profit focus of American society, have produced a culture in which the rich get richer and the poor are kicked to the side of the road.

Again. The poor get kicked to the side of the road. We have decades of data showing how the market focus of American health care has made our population sicker and poorer, worsened income inequality in the US and has disadvantaged the poor and people of color. You would have thought wed learned something from all our studies, and used what we learned to do a better job with Covid-19. Instead, we failed again, and failed so profoundly that we locked up our society for at least a year, and perhaps for as long as half a generation.

Still, because of my role with a community health center and with the two cities, I paid close attention to the stories and the data coming out of China in late 2019 and by January of 2020 was able to brief the mayors and my colleagues about what we were learning: This new Coronavirus is in the family of viruses that cause the common cold. This one likely evolved in bats and crossed over to human beings in the fall of 2019 in Wuhan China. It was related to the coronaviruses that cause SARS and MERS but this virus appeared to be harder to contain. In most people this new Coronavirus causes mild disease runny nose, fever, cough, loss of taste and smell, and sometimes nausea, vomiting, and diarrhea. But the new Coronavirus spreads quickly and can cause a very serious lung infection in some people, something called Adult Respiratory Distress Syndrome, which is much worse than a simple pneumonia and can be fatal in about one-third of the people who get significantly ill. The case fatality rate - the ratio of the number of people who get the disease to the number of people who die of it - was reported to be 3 percent, so that of a hundred people who would get the disease likely three would die, which made this Coronavirus 30 times more lethal than influenza but 20 times less lethal than Ebola, a virus that kills 50-75 percent of the people who get it.

Eventually wed learn the case fatality rate is more likely 0.4 percent or less, or about four times that of seasonal influenza. Even so thats a scary number, because every human being, in theory is susceptible to the Coronavirus, which means all of us could get sick at about the same time. In theory, a city of 100,000 might have 10,000 people in the hospital in the span of a few weeks, about ten times the usual number. And 3000, we thought then, would likely die. By comparison, about 5 percent of us are susceptible to seasonal flu each year. Even so, it kills 30,000 to 60,000 Americans every year. This means in that city of 100,000 people, likely 5000 people get the flu, and 500 people are hospitalized for it, and 5 die.

See the rest here:
What Was That? Coronavirus, Chaos and Democracy By Michael Fine PART 1 - GoLocalProv

Recommendation and review posted by Bethany Smith

Thanks to our ongoing global battle with the pandemic it looks like many nations will face some sort of covid-19 lockdown for the next six months a least. And given that for many of us it feels like restrictions had no sooner been lifted than they were reimposed, the result can be hard to bear psychologically, even if (thankfully) were unaffected physically.

However, help is at hand if you want to handle lockdown with the resolve, resilience and inventiveness of a ninja, take a look at these 7 ways to adapt to Covid-19 lockdown life.

You can literally learn to be a ninja online by watching free Ninja Learning Network training videos however please be careful not to injure yourself and seek advice from a physician before starting any strenuous fitness regime.

Been meaning to try that healthy vegetarian or vegan diet for some time? With so much plant-based food available online, theres never been a better time to switch your waistline will also thank you for it!

Creating some calm headspace for yourself is more important than ever during lockdown. If you dont want to adhere to Buddhist meditation practices, mindfulness is an effective secular version youll find on apps like Calm.

Always had a penchant for writing but never had the time to write down your thoughts? Writing a daily journal can be very therapeutic and your finished draft might turn into an autobiography or novel. Your lockdown diary could become a classic like Hagakure, still read hundreds of years after it was penned who knows?

Forget informal MOOCs where you put in the effort to study but dont get a recognised qualification in return take an online degree with ARU Distance Learning in a subject like digital marketing or psychology and you could be on your way to an exciting new career.

Being stuck indoors with family need not mean that youre at each others throats in fact it can be the ideal opportunity to build bridges and spend some quality time together. Spend a little less time on your phone or tablet and a little more time bonding over activities like cooking, crafts and simply chatting, then youll feel closer than ever to your loved ones.

Participating in a regular virtual pub quiz can be a great way of exercising those little grey cells and catching up with friends over a few convivial drinks. If youre struggling for ideas on how to get started, take a look at the amazing Jays Virtual Pub Quiz, which has taken the online world by storm this year!

Follow these seven ways to adapt to covid-19 lockdown life like a ninja and youll navigate the next few months like the most nimble shinobi you can thank us later!

Share youre lockdown tips in the comments section we would love to hear them.

See the original post here:
7 Ways To Adapt To the Covid-19 Lockdown Life Like A Ninja - Chiang Rai Times

Recommendation and review posted by Bethany Smith

Are you stressed, anxious, or depressed? Do you have trouble sleeping? Do you have skin and hair problems? The answer to all those queries can be CBD.

Cannabidiol, widely known as CBD, comes from cannabis plants and is one of the two prevalent compounds popular within the medical community. The other one, known as Tetrahydrocannabinol or THC, is responsible for the feeling high and the euphoric experience people experience.

Cannabis plants have two subspecies known as Cannabis Indica and Cannabis Sativa. Marijuana and hemp are both varieties of the Cannabis Sativa species, and CBD can be derived from both of them. Usually, hemp plants have been selectively bred and used industrially to remove THC almost completely. Marijuana, however, contains 30% of THC.

The breeding of hemp plants and CBD manufacturing has been legalized for medicinal reasons as long as it contains no more than 0.3% of THC per dry weight. CBD derived from marijuana is also legally manufactured but usually requires a doctors prescription to be sold.

CBD derived from both marijuana and hemp plants is used to treat many medical issues such as nausea (from chemotherapy), stress, anxiety, pain management, and treating muscle spasms that can be brought on due to multiple sclerosis, etc. It works on the neurotransmitters and regulates the nerve cells in our brains and tells them to calm down. This year, with the coronavirus pandemic going around, many people are stressed and have a heightened anxiety level than before for staying at home for too long or from losing jobs. It brings a feeling of relaxation to the patients who suffer from these issues and helps them sleep and relax. Another use of this compound is it is excellent in reducing acne and improves skin and hair conditions.

Products containing CBD are everywhere now, in hair products, skin products, capsules, oil, pet products, etc. It was also included in some food items as additives until the FDA banned it in 2019.

However, for ingesting, there are different methods that you can use that would best suit your needs. You can try inhaling, vaping, taking capsules orally, or ingesting oil drops. You can even choose what type of flavor or aroma you prefer.

The most effective relaxant that promotes the wellness of health is CBD-containing oil supplements. If you are new to using this, you can start with a low dosage and increase it as you see fit. Labels stating CBD oil have a significant amount of CBD not to be confused by hemp oil, which doesnt contain any CBD. You can buy CBD oil UK and notice how it boosts your mood and relaxes you.

Its simple. These oils come with an ml dropper and labeled instructions on how much dosage should be taken. It is usually recommended to start low, about 5mg, and then making your way up. Drop 5mg of oil under your tongue and keep it that way for around 60 90 seconds and then swallow. This way, you can retain the full potency of the product. Another thing to remember is that CBD oil drops can be taken after every six to eight hours. Ideally, you should use cannabinoids in consistent doses.

Side effects due to ingesting CBD have not been reported yet, or they are so mild that it was not directly attributed to cannabidiol. The ones reported were mild dry mouth and thirst, although they are not proven to be caused by CBD.

With the arrival of a pandemic and lockdown situation, most people have become anxious, depressed, and stressed financially and mentally. Some opt to take marijuana or other drugs and leave their problems behind, but the compound itself is so addictive that people keep asking for more. So when they finally decide to quit, they go through severe withdrawal issues. CBD has been known to help patients like these and manage mental health issues such as psychosis.

If you have skincare issues such as eczema and psoriasis, then using CBD topical products has been known to reduce oil production and eradicate acne. It contains anti-inflammatory agents that help in clearing out the skin.

CBD also helps with back pain or injury that involves inflammation; however, more studies are yet to be conducted.

As for stress-related issues, CBD has proven to relax the nerve cells and signals the body to take it slow. It acts as a mood regulator and reduces anxiety, hence re-balancing a persons mental and emotional health.

CBD therapy has also been shown to help health-care workers in this pandemic by providing relief to their neck or back pains and aid in restoring their sleep. It also helped many people who had panic attacks and were suffering from depression and the insomniacs affected due to the ongoing lockdown situation.

CBD reacts differently in men and women, where the latter is usually sensitive to the chemical compounds effects due to their hormone, estrogen. Women can develop a tolerance level within their bodies, so they must take a break now and then. A break from CBD will ensure their endocannabinoid system resets and help them adjust better to the product.

Despite CBD showing promising results, it is always good to consult your physician before making CBD a part of your life. It is particularly crucial to consult your doctor if you are taking other medications for your health issues such as antidepressants, which may have a side effect if combined with CBD.

CBD, with its therapeutic benefits, taken in appropriate amounts can lead to a better and healthier lifestyle, mentally, emotionally, and physically. However, a relationship with this compound requires you to put in a bit of work and make your life easier in this lockdown situation.

Read this article:
How Effective is CBD for your Health - Oregon Cannabis Connection

Recommendation and review posted by Bethany Smith

An appeal has gone out to help an 11-year-old girlwho needs a stem cell transplant from a stranger, to give her a second chance of life.

Arya was diagnosed with a rare blood disorder. But following a diagnosis of aplastic anaemia, a serious condition that occurs when the body stops producing enough new blood cells, she will also be starting immunosuppressant treatment.

This means her immune system isn't working as it should, putting her at a greater risk of infections.

To cure her aplastic anaemia Arya needs a lifesaving stem cell transplant. Blood cancer charity Antony Nolan is searching the worldwide stem cell registers for a donor whose tissue type matches Arya's and who is willing to donate their stem cells to help her live a normal life again.

However, the search for a perfect match is difficult for people like Arya, who is half Indian, with mixed ethnicity so she is sharing her story with Anthony Nolan in order to raise awareness of the need for more people of mixed race to join the stem cell register.

She said, "'They said it would be hard to find a donor for me because of my ethnicity but it isn't impossible. There is hope."

The best possible match for Arya is most likely to have the same background or mix of ethnicities. Currently, people with mixed Asian or other minority backgrounds have a 20% chance of finding a match from an unrelated donor, compared with nearly 70% for people with white, north European heritage.

Arya was diagnosed earlier this year and is receiving treatment at St Mary's Hospital, London.She added, 'When I first became unwell, I remember getting a stomach ache. At first it felt like a stitch but the pain didn't go away so I had more tests.'

These tests revealed something more serious. Arya's mum Brundha recalls: "Arya has always been fit and healthy, but life changed very quickly; all of a sudden we were talking to doctors about aplastic anaemia and Arya has had to stop many of the things she liked doing because her platelets, the tiny blood cells that help your body form clots, were low."

The family were given news of the treatment Arya would need to undergo and the need for a suitable donor.As the search continues, waiting for a match for Arya has inspired the Lloyd family to share their story. Their aim is to raise awareness of the need for more stem cell donors of mixed ethnicities to join the Anthony Nolan register and so increase the likelihood of finding a match for young people like Arya.

Brundha said: 'Because Arya is of mixed race, it was always unlikely we would find a match quickly. We have therefore started this appeal because we don't want to give up hope. It's a waiting game, but there could be someone out there who is a match. We also understand that younger people make better matches, so we would like to do all we can to make this more widely known.'

Aryas Consultant, Professor Josu de la Fuente, who is a Consultant Haematologist and Director of the Paediatric Bone Marrow Transplant Programme at Imperial College Healthcare in London said A well matched donor offers the best opportunity for Arya to establish normal blood production long-term and not to worry about the future.

"I will urge anyone, but particularly those of mixed ethnicity to consider joining the Anthony Nolan register so that no child with blood disorders faces an uncertain future: we can all contribute and be part of the solution.

Arya added: 'What stands out most for me are the bone marrow biopsies and being undergeneral anaesthetic for the first time.'

Rebecca Pritchard leads Anthony Nolan's work to recruit donors aged 1630 to its stem cell register. Rebecca says: 'Despite all she is going through, Arya is standing up to share her story in order to inspire people of mixed background to join the register. There is a potential lifesaver out there who could help her. If you're aged 1630 you can join the Anthony Nolan register online by completing a form and swabbing your cheeks with swabs we'll send in the post.

'Each time we're told a patient is in need of a transplant we'll check whether you're a match for them; if you're found to be a match you could give your stem cells to give hope to families like Arya's.'

Brundha said, 'We were unprepared for this and when it happens you want to know there is a source of donors for your child. That's why we're doing this to highlight the need. Being on the register could have a major impact on someone else's life. It's such an important thing you could do without realising.

"Families would be eternally grateful. You may never be called on, but if you are you could be a lifeline for someone. One person out there could be that person. It's a win-win for everybody.'

Arya added: 'The message I would like people to take away is Never give up hope and please join the register.

To find out more about joining the Anthony Nolan register, or to find out more about how you can support the charity click here

Original post:
'Never give up hope and please join the register' says 11-year-old in need of stem cell donor match - Asian Image

Recommendation and review posted by Bethany Smith

In the latest Stem Cell Banking market report, factors that are positively impacting the industry progression as well as the major threats & challenges existing in this domain are expounded. To unveil all the possible opportunities for business expansion, the study scrutinizes the regulatory and macroeconomic framework across the various geographies. It also delves into the competitive dynamics and evaluates how it will evolve during the forecast period. Further, it suggests strategies for dealing with the impact of the COVID-19.

Key highlights from COVID-19 impact analysis:

A gist of the regional landscape:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/218931

Other highlights from the Stem Cell Banking market report:

Market Status:The complete details on Stem Cell Banking Market situation, principal regions, distribution channels, pricing structures are blanketed.

Why Buy this Report?

Strategic Analysis Covered in TOC: - Key Topics Covered

Initially, the document offers an outline of the global market with a complete take a look at key drivers, constraints, challenges, traits and product types sold by using the employer. The file studies the Stem Cell Banking market capacity of key packages with the identity of forecast opportunities. The local evaluation with a focus on specific international locations and area of interest markets is presented. The pinnacle organization profiles with key-word market size and proportion estimation, revenue strategies, products, and other factors are studied.

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/218931

Read the original here:
Stem Cell Banking Market to witness an impressive growth during the forecast period 2020 2025 - Express Journal

Recommendation and review posted by Bethany Smith

The global blood and bone marrow cancer treatment market was valued at $38.8B (approx 32.8B) in 2018 and is reportedly expected to reach $74.9B (approx 63.4B) by 2027, expanding at a CAGR of 7.7% from 2019 to 2027.

Blood cancer begins in the bone marrow which is the integral source of stem cells, which are later differentiated into different types of blood cells in the human body. Researchers have stated that approximately 1.85 million new cases of blood cancer will be diagnosed by 2040 throughout the globe.

These are the top global tech PR agencies you should absolutely check out in 2020

Europe holds a market share of 30.8% owing to the supportive regulatory framework provided by the European Medical Agency for the development and sale of medication for the treatment of blood cancer.

In the recent development, blood and bone marrow cancer treatment developer Priothera Limited, has raised 30M in its Series A round of funding led by Fountain Healthcare Partners with participation from co-lead investor HealthCap and funds managed by Tekla Capital Management, LLC, as well as EarlyBird Venture Capital.

According to the medtech startup, the raised funds will be used to progress the clinical development of mocravimod a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogenic hematopoietic stem cell transplantation (HSCT) for treating AML.

Priothera expects to generate further randomised clinical data in high-risk AML patients with these funds.

Dublin-based Priothera was founded in 2020 by Drs. Florent Gros and Dhaval Patel. Joining the founding team include experienced industry executive, Dr. Christoph Bucher, Dr. Simone Seiter, and CFO Brice Suire.

The company claims to be leading the way in developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. S1P receptor modulators have been suggested to largely reduce egress of T cell subsets from lymphatic tissues allowing for dual inhibition of graft-versus-host-disease (GvHD) and enhancing graft-versus-leukemia benefits in patients receiving allogenic stem cell transplant.

Allogenic stem cell transplant is the only potentially curative approach for AML patients but has unacceptably high mortality with current treatments, says Florent Gros, co-founder, and CEO of Priothera.

Florent Gros further adds, We are excited about mocravimod which has a unique mechanism of action and clinical proof of concept demonstrating its ability to improve survival outcomes for this devastating disease.

Acute myeloid leukemia (AML) is an aggressive and highly proliferative form of cancer where the bone marrow generates abnormal myeloblasts (a type of white blood cell). According to the company, AML is the most common form of leukemia in adults and can metastasise quickly if left untreated. This can typically lead to death within a few months of diagnosis.

Priothera has acquired rights to a drug called mocravimod from Japans Kyorin Pharmaceutical for the treatment of acute myeloid leukaemia.

According to the company, Mocravimod has already been extensively tested in multiple immunologic indications and has shown a survival benefit in an early clinical study evaluating acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) patients undergoing hematopoietic stem cell transplantation (HSCT).

Priothera is developing mocravimod in AML with the aim of enhancing the curative potential of Hematopoietic Stem Cell Transplantation (HSCT). The company claims that promising early clinical results have revealed that mocravimod has the potential to rebalance the patients immune system by decoupling Graft-versus-Host Disease (GvHD) from Graft-versus-Leukemia (GvL), preventing the first and preserving the latter.

Following the closing of the financing, people who have joined the Board of Directors include Florent Gros (Priotheras co-founder and CEO), Dr. Dhaval Patel (Priotheras co-founder and CSO at UCB), Dr. Manus Rogan (Fountain Healthcare Partners co-founder and MD), Dr. Marten Steen (partner at HealthCap), Dr. Henry Skinner (senior vice president at Tekla Capital Management, LLC) and Lionel Carnot (partner at EarlyBird Venture Capital).

Image credits: Jarun Ontakrai/ShutterStock

Follow this link:
This Dublin-based startup raises 30M to develop promising therapies for leukemia - Silicon Canals

Recommendation and review posted by Bethany Smith

Photo composition: Claudia Garca Martnez

Dr. Odalis Mara de la Guardia Pea, an expert immunologist, describes as "encouraging" preliminary findings obtained at the conclusion of the first phase of clinical trials evaluating the use of stem cells in patients facing lung damage caused by COVID-19.

The study, begun during the month of May at the Cuban Institute of Hematology and Immunology (IHI), was undertaken with a view toward eliminating or reducing interstitial inflammatory or fibrotic lung lesions following the infection.

The doctor, also an infectious disease specialist and head of External Services at the IHI, explains that the research will have significant impact "if, as we hope, stem cell therapy produces positive results in these patients with pulmonary alterations post-COVID-19.

"If the treatment is effective, it will be generalized across the entire country, improving the quality of life and respiratory capacity of these patients," she stated with the enthusiasm of someone devoted to the most important mission in the world: saving lives.

THE LUNG, THE "TARGET" ORGAN

De la Guardia Pea commented that, although SARS-COV-2 has a variety of dissimilar effects (cardiovascular, renal, cerebral, vascular, in distal or lower limbs, and others); the "target" organ in the case of COVID-19 is the lung, in which patients experience the most serious impact, both during the disease and once they have recovered, a pattern being studied internationally.

"We have detected cases, specifically in Cuban patients, who have presented this kind of affectation, especially those who have suffered symptoms over a longer period. Among those visited for the study, there were cases of important pulmonary alterations, which is the most frequent, but perhaps not the most serious," the specialist continued.

RECRUITMENT OF VOLUNTEERS

"These recruitment consultations were atypical, as they were done in the field, visiting the homes of recovered patients," the doctor explained, adding that potential volunteers needed to meet several criteria for inclusion in the clinical trials.

Those selected were between 18 and 70 years of age, of both sexes, who had contracted COVID-19 thirty days prior to the trial treatment, testing negative on a PCR at the time of recruitment, and exhibited respiratory symptoms since the beginning of the disease.

Specifically sought for the trials were patients who experienced a more torpid evolution of the disease, those who were hospitalized for more than 20 days, requiring oxygen, assisted ventilation, or the use of some aerosol as treatment, upon reaching serious or critical condition.

"More than 130 homes were visited over almost three months, from May to June; and 141 patients were interviewed, of which about 50 were studied. Twenty patients were included in the trial, which was the determined number," the doctor reported.

PULMONARY SEQUELAE

"During the investigation, several long term effects of COVID-19 were noted, although the most frequent involved the lungs. In some cases, indications of pulmonary fibrosis were detected, a condition that cannot be completely corrected, and can only be treated to increase lung capacity and improve quality of life," the doctor explained.

"The study is still in progress. The first phase has been completed, but there is some time remaining before final evaluation of the patients. What we can say is that, thus far, we are very happy with the results we have observed, they are encouraging," she emphasized.

UNFORGETTABLE STORIES

-Could you recount some stories that particularly impacted you?

-The first day I went out to recruit volunteers, I arrived at the home of a patient who, when she opened the door, exhibited obvious difficulty breathing, evident in plain sight.

We conducted the interview and learned that she experienced this difficulty on a daily basis, five weeks after being diagnosed with COVID-19 and 15 days after a negative PCR test.

This case was significant because we became aware of the lingering effects some patients face, who after having the disease, being discharged and completing all treatment, can have symptoms for a long time.

On another occasion, a patient received us effusively, grateful that he would continue to be treated, that he would receive some follow-up. This attitude was very common in many cases, confirming for us that the patients we visited were still feeling unwell, despite having recovered and been discharged from the hospital.

YOU CAN BE ASYMPTOMATIC OR YOU CAN DIE

"You can be infected and be asymptomatic, or develop the most severe symptoms of the disease and die. This is random, no one understands or can control it," the specialist warns, emphasizing the importance of being fully conscious of taking care of ourselves, since anyone can develop an aggressive case of COVID-19.

"I agree with everything Professor Durn says every day at nine o'clock in the morning, about how measures must be maintained and complied with: the use of facemasks, hand washing, shoe disinfection (with doormats soaked in 0.5% hypochlorite at the entrance to common areas), social distancing, and collective discipline.

"The population must take care; success in containing the pandemic lies in individual responsibility," she concluded.

STEM CELL TREATMENT

-When the patient is included in the study, treatment begins by injecting the granulocyte colony stimulating factor, Ior Leukocim, a product manufactured at Cubas Center for Molecular Immunology, to achieve the mobilization of stem cells from the bone marrow to the bloodstream.

-Subsequently, the patient's blood is extracted and mononuclear cells are separated and concentrated.

-This pool of cells includes hematopoietic and non-hematopoietic stem cells, which have immune-regulatory properties and promote the disappearance of lesions and the reconstitution of lung tissue.

-The cells are infused intravenously.

-The patient is evaluated one month following treatment and again at six months, to determine the clinical efficacy of the stem cell therapy.

Source: Granma interview with Consuelo Macas Abraham, director of the National Institute of Hematology and Immunology.

Read the original:
Clinical trials with stem cells to treat effects of COVID-19 in the lungs advance - Granma English

Recommendation and review posted by Bethany Smith

How is the tool different from other editing systems? Is there a possibility of the tool being misused?

The story so far: The 2020 Nobel Prizes for sciences announced this week made history of sorts when one of it was exclusively shared by two women. Scientists Jennifer Doudna and Emmanuelle Charpentier bagged the Nobel Prize for Chemistry for the development of a method for genome editing. The discovery of one of gene technologys sharpest tools: the CRISPR/Cas9 genetic scissors will lead to the emergence of novel biological applications by making it easier to edit genes, and may make the dream of curing inherited diseases come true.

Much like what Microsoft (MS) Word does for writing, the CRISPR/Cas9 system allows for adding, altering and deleting the genomic code in living beings. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are pieces of DNA that bacteria snip off from viruses that once attacked them, much like file names used to store various documents we write in MS Word.

The COVID-19 pandemic has brought to the fore the importance of memory cells, which can quickly produce relevant antibodies to neutralise a repeat infection by a virus. Similarly, the CRISPR are a part of bacterias immunological systems that help them in recognising threatening viruses. When they sense a lurking virus, the bacteria produce customised RNA, which is necessary to translate DNA into protein, gleaned from the CRISPR libraries. This also contains Cas (CRISPR-associated) genes that are used to produce enzymes such as Cas-9. These enzymes the Cas-9 being a particularly popular one can be used to chop the DNA of the virus and destroy them.

Using the tool, researchers can change the DNA of animals, plants and microorganisms with precision. Emmanuelle Charpentier, who is now director, Max Planck Institute for Infection Biology, Berlin, had studied Streptococcus pyogenes, a species of bacteria known to be associated with a range of illnesses such as pharyngitis, tonsillitis and scarlet fever. While studying this, she discovered a previously unknown molecule, tracrRNA. Her work showed that tracrRNA is part of bacterias ancient immune system, CRISPR/Cas, that disarms viruses by cleaving their DNA, the Nobel release explains. Dr. Charpentier published her discovery in 2011. The same year, she initiated a collaboration with biochemist Jennifer Doudna, now a professor at the University of California, Berkeley.

Together, they succeeded in recreating the bacterias genetic scissors in a test tube and simplifying the scissors molecular components so they were easier to use, says an explainer on the Nobel Prizes website on their work. In a significant experiment, they reprogrammed the genetic scissors. In their natural form, the scissors recognise DNA from viruses, but Charpentier and Doudna proved that they could be controlled so that they can cut any DNA molecule at a predetermined site. Where the DNA is cut it is then easy to rewrite the code of life, the note adds.

Also read | What is genome editing

Other genome editing systems like TALENs and Zinc-Finger Nucleases can do similar jobs, but several users consider the Charpentier-Doudna tool more adaptable and easier to use.

It is less than a decade since this system gained wide research and commercial interest, but in the past few years, scientists have been able to make precise single-base-pair changes or larger insertions. Coupled with the availability of genome sequences for a growing number of organisms, the technology allows researchers to find out what genes do, move mutations that are identified and associated with disease into systems where they can be studied and tested for treatment, or where they can be tested in combinations with other mutations.

Editorial | Scissoring the DNA

The commercial potential of the system is so compelling that within years of its development, there was a battle over the ownership of the intellectual property rights of the CRISPR/Cas9 involving the University of California and the Massachusetts Institute of Technology's Broad Institute. The essence of this was that Feng Zhang of the Broad Institute had discovered a way to deploy the system in eukaryotic cells (that make up animal cells), whereas Dr. Doudnas patent application covered the process more generally. Dr. Zhangs patent was granted before Dr. Doudnas application. The patent dispute is still ongoing, and both sides claim victory in terms of the commercial application of the patents.

Also read | CRISPR-Cas gene editing causes crisper debates

The prize to CRISPR/Cas9 may be unusual as it is rare for a method to be announced and conferred a Nobel within a decade of its discovery, but it underlines its game-changing potential. In the last five years, both Dr. Doudna and Dr. Charpentier have been recipients of several important prizes in sciences.

Earlier this year, a person with hereditary blindness became the first to have a CRISPR/Cas-9-based therapy directly injected into her body. Gene-editing company CRISPR Therapeutics announced in June that two patients with beta thalassemia and one with sickle cell disease would no longer require blood transfusions after their bone marrow stem cells were edited using CRISPR techniques.

Earlier this week, according to a report in Chemistry World, Dr. Doudna launched a new company, Scribe Therapeutics, to begin work on treatments for amyotrophic lateral sclerosis. Reuters reported that Dr. Doudna is already employing CRISPR in the battle against the COVID-19 as a co-founder of biotech startup Mammoth, which has tied up with GlaxoSmithKline to develop a test to detect infections.

This year, the CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) in Delhi developed a COVID-19 testing kit, nicknamed Feluda, after the fictional Bengali detective, based on the CRISPR/Cas9 system. There are commercial CRISPR-based home kits that allow amateur researchers to develop their own biotechnology applications, triggering a sub-culture called bio-hacking.

Also read | Change in ICMR rules stalls COVID-19 test kits from government labs

Research is already underway for using proteins that are smaller and more efficient than Cas-9, though the system purportedly holds promise for treating more complex diseases, such as cancer, heart diseases, mental illnesses, and the human immunodeficiency virus (HIV) infection.

The most controversial application of CRISPR/Cas9 was in 2018, when Chinese researcher He Jiankui announced that he had used it to create gene-edited twins Lula and Nana via in-vitro fertilisation. He used the gene scissors on the children when they were embryos to edit a gene, CCR5, that in its modified form would ostensibly protect the babies from HIV. The HIV uses the CCR5 to infect cells and the modified gene would shut the door against such an entry. He was widely condemned and sentenced to three years in jail, and stripped of his position at Shenzhen University, where he worked.

Also read | How safe is CRISPR?

While he broke a number of medical rules, what is particularly controversial is that the specific mutations that would supposedly protect the children from HIV were not achieved. There were a host of other unintended mutations too. It is not known how these mutations are going to play out over the children's lifetimes and whether they will spread to humanity more widely in due course. Thus, even though the CRISPR/Cas-9 system allows a democratic usage in labs across the world to tinker with genomes, it still has not reached the level of precision required to be sure that it does not cause unintentional side effects.

This year has seen a remarkable representation of women. Four women have been named Nobel Laureates in 2020 against five men so far. The Sveriges Riksbank (Swedens national bank) Prize for economics, or the 'economics Nobel', will be announced next week. The 2001-2019 interval has seen the maximum number of women Laureates 24 compared to just 11 from 1981 to 2000 and 7 from 1961 to 1980. There were only 12 women Laureates from 1901 to 1960. Only one woman, Marie Curie, has been honoured twice, with the 1903 Nobel Prize in Physics and the 1911 Nobel Prize in Chemistry.

Many women think that no matter what they do, their work will never be recognized the way it would be if they were a man, Al Jazeera quoted Dr. Doudna as saying. And I think (this prize) refutes that. It makes a strong statement that women can do science, women can do chemistry, and that great science is recognised and honoured.

See the original post:
The Hindu Explains | How does a genome editing tool developed by two women scientists help in tackling diseases? - The Hindu

Recommendation and review posted by Bethany Smith

Using a brush or comb, in the shower, passing your hand through your hair In a 2015 IFOP survey, three out of four French people (76%) without baldness declared that they lost their hair. In addition, after 65 years, three in ten men suffer from androgenetic alopecia (or baldness). In general, therefore, we often see a loss of density with age, both in men and in women. However, science has long looked into the phenomenon of age-related hair loss, both to understand its origin and to treat it. Focusing on stem cells seems to offer the best hope for a cure, based on numerous studies.

The hair transplant procedure is indeed a sometimes expensive and invasive procedure. As for drugs, finasteride used for androgenetic alopecia in men can induce side effects such as loss of libido and erectile dysfunction while minoxidil can cause hypertrichosis. Today, researchers therefore seem to be looking more at alternative solutions, and in particular by focusing on stem cells.

Stem cells, directly linked to hair lossFor decades, researchers have always focused on keratinocytes, cells that make up the epidermis and integuments (body hair, hair, etc.). However, as part of a study conducted by the University of Calgary (Canada), the team of researchers focused on a small cell group present in hair follicles and in skin stem cells. : fibroblasts. And according to them, these fibroblasts are the main cause of age-related hair loss.

By studying the sparse coat of elderly mice, they noticed that fibroblast stem cells had lost their regenerative function or were malfunctioning. There werent enough of them to regenerate fibroblasts. As a result, the fibroblasts and hair follicles began to miniaturize and were no longer able to produce hair, explains Biernaskie, head of the research team.

Remember that fibroblasts are important because they send messages to keratinocytes to force them to divide, and in so doing, orchestrate the growth cycles of hair follicles allowing the production of new hairs. When the fibroblasts become scarce, the signal then becomes too weak to reach the keratinocytes and maintain the process of capillary growth. For Jeff Biernaskie: if we want to one day succeed in preventing hair loss or re-grow those that are already falling, we must work to preserve the function of these stem cells which are found in the hair follicles.

Against hair loss, but not only!This finding may help guide future research on hair loss more precisely. Scientists at the University of Calgary are particularly hoping to find a way to prevent this degeneration by blocking certain genetic mutations that occur directly in stem cells in fibroblasts.

They also believe that this will have wider implications. Indeed, Wisoo Shin, lead author of the study, points out that similar fibroblasts are found in most of our organs, maintaining their integrity and promoting tissue regeneration. Finding a way to promote self-renewal to produce new functional fibroblasts into old age therefore also offers the hope of being able to treat certain injuries and help the skin to regenerate.

Lamia spent a couple of years interning at an organization that offered medical consultation before joining the editorial team at FLWL News. An enthusiastic fitness freak in the room, she offers the best amounts of insights and craft-based writing style to keep us up to date about the medicine industry, health and science.

Email:lamia@flwl.orgPhone: +1 512-845-8162

See the article here:
Stem cells are believed to play a key role in hair loss - FLWL News

Recommendation and review posted by Bethany Smith

Electric organoid: Neurons derived from people with 22q11.2 syndrome are hyperexcitable and show calcium-signaling deficits.

Courtesy of Pasca lab

Neurons derived from people with 22q11.2 deletion syndrome, a genetic condition linked to autism, show deficits in electrical activity and calcium signaling, according to a new study1. A single gene appears to be largely responsible for these defects, the study shows.

Up to 20 percent of people who lack part or all of the chromosomal region 22q11.2 have autism. Individuals with the deletion may also have schizophrenia, seizures, heart defects, immune dysfunction or learning problems.

The new findings uncover factors that may contribute to the development of psychiatric conditions associated with 22q11.2 deletion syndrome. They could also help researchers identify new therapeutic targets, says lead author Sergiu Pasca, associate professor of psychiatry and behavioral sciences at Stanford University in California.

The syndrome is relatively common, occurring in up to 1 in 4,000 newborns, Pasca says. But researchers do not fully understand how genes in the 22q11.2 region contribute to autism or other conditions, he adds.

To solve this molecular puzzle, Pasca and his team reprogrammed skin cells from 15 people with the deletion and 15 controls into induced pluripotent stem cells. Using a technique they developed in 2015, they coaxed these cells to turn into neurons, which self-organize in a dish into spherical clusters called organoids. The organoids show some key features of the developing cerebral cortex, a brain region implicated in autism.

The neurons derived from people with 22q11.2 syndrome spontaneously fire four times as frequently as neurons derived from controls, the researchers found. And the electrical activity of the 22q cells does not set off the usual spike in calcium levels, which is crucial for neurons to exchange messages.

In some other syndromes tied to schizophrenia and autism, calcium-channel genes are mutated. But the number of channels and the speed at which they work in 22q neurons is the same as in control neurons. Instead, the 22q cells show an unusually low voltage difference across the cell membrane when they arent firing, causing the signaling defects and hyperexcitability, the researchers found.

The researchers suspected that a gene called DGCR8 might be responsible for the neuronal deficits in the organoids because it lies within 22q11.2 and is linked to abnormal electrical activity in the neurons of mice2. DGCR8 is essential for the synthesis of short RNA fragments, called microRNAs, that regulate gene expression.

Lowering DGCR8s expression levels in control neurons reproduced the abnormalities seen in 22q neurons. In contrast, boosting the genes activity in 22q neurons or treating them with antipsychotic drugs prevented them from being overly excitable and reversed their calcium-signaling defects. The study was published 28 September in Nature Medicine.

Previous studies have analyzed lab-grown neurons derived from people with schizophrenia or autism-related disorders such as Rett and fragile X syndromes. But most used only a few human-derived cell lines, says Guo-li Ming, professor of neuroscience at the University of Pennsylvania in Philadelphia. The new study, Ming says, has a total of 30 human lines thats a huge effort.

By studying brain organoids derived from so many people, the researchers were able to identify the gene that might be involved in the psychiatric conditions associated with 22q11.2 syndrome, says Sally Temple, scientific director of the Neural Stem Cell Institute in Rensselaer, New York. Whenever we have a light shining ahead, saying, This is what you should really be looking at, it means that were making progress, she says.

The study participants with 22q11.2 syndrome vary in their psychiatric diagnoses, and yet all the brain organoids derived from their cells show the same neuronal abnormalities. Thats somewhat surprising, because we know there are a lot of differences in the genetic background of different people, Ming says.

The deletion might conspire with other factors to ultimately determine which psychiatric conditions a person has, Pasca says. It could be that the deletion causes cellular defects, and once there is a stressor such as social stress, disease develops. Its also unclear whether these cellular defects are related to the high prevalence of seizures in people with 22q11.2 syndrome, he says.

The hallmarks of most neuropsychiatric conditions can change over time, says Giuseppe Testa, director of the stem cell epigenetics unit at the European Institute of Oncology in Milan, Italy. Studies that look at a larger number of people with 22q11.2 deletion syndrome or other neurodevelopmental conditions could help to elucidate the relationship between the neuronal defects observed in the lab and the psychiatric manifestations of the conditions, Testa says. The new study, however, is a great resource for understanding how the 22q11.2 deletion contributes to schizophrenia and autism, he says.

Pascas team is trying to pinpoint molecules that could open new therapeutic avenues for 22q11.2 deletion syndrome. The antipsychotics they tested restore the unusual voltage differences in the 22q neurons, but they dont address the core mechanisms responsible for psychiatric conditions linked to the syndrome, Pasca says.

Whats more, antipsychotics have many side effects, and not all individuals respond to them, he says. We need better therapies we need to identify what the key molecular players are and target those.

Here is the original post:
Brain organoids reveal neuronal flaws in syndrome tied to autism - Spectrum

Recommendation and review posted by Bethany Smith

TOKYO and BOTHELL, Wash., Oct. 12, 2020 /PRNewswire/ --Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201. The cohort is evaluating the antibody-drug conjugate PADCEV (enfortumab vedotin-ejfv) for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor and have not received a platinum-containing chemotherapy and are ineligible for cisplatin. Results showed a 52 percent objective response rate (ORR) [95% Confidence Interval (CI): 40.8, 62.4] per blinded independent central review and a median duration of response of 10.9 months. The most frequently reported treatment-related adverse events Grade 3 or greater that occurred in more than 5 percent of patients were: neutropenia, rash, fatigue, increased lipase, diarrhea, decreased appetite, anemia and hyperglycemia. Data from cohort 2 of the trial will be submitted for presentation at an upcoming scientific congress and will be discussed with regulatory authorities.

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.1,2 The U.S. Food and Drug Administration (FDA) granted accelerated approval to PADCEV in 2019 based on results from the first cohort in this trial, which included patients whose disease hadprogressed during or following platinum-based chemotherapy and a PD-1/L1 inhibitor.

"Advanced urothelial cancer in patients who have received immunotherapy and are ineligible for cisplatin is a particularly difficult disease to treat," said Arjun Balar, M.D., Associate Professor of Medicine, Director Genitourinary Medical Oncology Program, NYU Laura and Isaac Perlmutter Cancer Center, NYU Langone Health and an investigator for the trial. "Typically, these patients are frail, suffer from multiple comorbidities beyond their urothelial cancer and are not able to tolerate additional treatment beyond immunotherapy, leading many to discontinue therapy altogether."

"We are committed to developing new treatments for patients with hard-to-treat cancers, such as those with locally advanced or metastatic urothelial cancer that has progressed following treatment with a PD-1 or PD-L1 inhibitor and who are ineligible for cisplatin therapy," said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head, Astellas. "We look forward to discussing these data with regulatory authorities including the FDA."

"This is the first trial to report objective responses in patients with advanced urothelial cancer who had previously received immunotherapy but were ineligible for cisplatin in this setting due to inadequate kidney function or other conditions," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "These promising new data from EV-201 may support a regulatory application to extend use of PADCEV in U.S. patients whose cancer has progressed after immunotherapy and who are ineligible for cisplatin."

Urothelial cancer is the most common type of bladder cancer (90 percent of cases), and can also be found in the urothelial cells that line the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra.3 Globally, approximately 580,000 people will be diagnosed with bladder cancer in 2020, and bladder cancer will be attributed to approximately 210,000 deaths worldwide.4

About the EV-201 TrialThe EV-201 trial (NCT03219333) is a single-arm, pivotal phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1 or PD-L1 inhibitor, including those who have also been treated with a platinum-containing chemotherapy (cohort 1) and those who have not received a platinum-containing chemotherapy in this setting and who are ineligible for cisplatin (cohort 2). The trial enrolled 128 patients in cohort 1 and 91 patients in cohort 2 at multiple centers internationally.5 The primary endpoint is confirmed objective response rate per blinded independent central review. Secondary endpoints include assessments of duration of response, disease control rate, progression-free survival, overall survival, safety and tolerability.

For more information about the EV-201 clinical trial, please visit clinicaltrials.gov.

About PADCEV (enfortumab vedotin-ejfv)PADCEV was approved by the U.S. Food and Drug Administration (FDA) in December 2019 and is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery or in a locally advanced or metastatic setting. PADCEV was approved under the FDA's Accelerated Approval Program based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.1

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.1,2 Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).2 PADCEV is co-developed by Astellas and Seagen.

PADCEV Important Safety Information

Warnings and Precautions

Adverse ReactionsSerious adverse reactions occurred in 46% of patients treated with PADCEV. The most common serious adverse reactions (3%) were urinary tract infection (6%), cellulitis (5%), febrile neutropenia (4%), diarrhea (4%), sepsis (3%), acute kidney injury (3%), dyspnea (3%), and rash (3%). Fatal adverse reactions occurred in 3.2% of patients, including acute respiratory failure, aspiration pneumonia, cardiac disorder, and sepsis (each 0.8%).

Adverse reactions leading to discontinuation occurred in 16% of patients; the most common adverse reaction leading to discontinuation was peripheral neuropathy (6%). Adverse reactions leading to dose interruption occurred in 64% of patients; the most common adverse reactions leading to dose interruption were peripheral neuropathy (18%), rash (9%) and fatigue (6%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions leading to dose reduction were peripheral neuropathy (12%), rash (6%) and fatigue (4%).

The most common adverse reactions (20%) were fatigue (56%), peripheral neuropathy (56%), decreased appetite (52%), rash (52%), alopecia (50%), nausea (45%), dysgeusia (42%), diarrhea (42%), dry eye (40%), pruritus (26%) and dry skin (26%). The most common Grade 3 adverse reactions (5%) were rash (13%), diarrhea (6%) and fatigue (6%).

Lab AbnormalitiesIn one clinical trial, Grade 3-4 laboratory abnormalities reported in 5% were: lymphocytes decreased (10%), hemoglobin decreased (10%), phosphate decreased (10%), lipase increased (9%), sodium decreased (8%), glucose increased (8%), urate increased (7%), neutrophils decreased (5%).

Drug Interactions

Specific Populations

For more information, please see the full Prescribing Information for PADCEV here.

About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website athttps://www.astellas.com/en.

About Seagen Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit http://www.seagen.com and follow @SeagenGlobal on Twitter.

About the Astellas and Seagen CollaborationAstellas and Seagen are co-developing PADCEV (enfortumab vedotin-ejfv) under a collaboration that was entered into in 2007 and expanded in 2009.

Astellas Cautionary NotesIn this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

Seagen Forward Looking StatementsCertain statements made in this press release are forward looking, such as those, among others, relating to the submission of data from cohort 2 of the EV-201 trial for presentation at an upcoming scientific congress; intended regulatory actions, including the potential submission of a regulatory application to extend the use of PADCEV in U.S. patients or plans to discuss data from cohort 2 of the EV-201 trial with regulatory authorities; and the therapeutic potential of PADCEV, including its efficacy, safety and therapeutic uses. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include that the data from cohort 2 of the EV-201 trial may not be selected for presentation at scientific congresses; the possibility of delays in the submission of any regulatory application to extend the use of PADCEV in U.S. patients; that the results from cohort 2 of the EV-201 trial may not be enough to support any approvals by regulatory authorities; that any product labeling that is approved may be narrower or less desirable than anticipated; the risk of adverse events or safety signals; and the possibility that adverse regulatory actions may occur. More information about the risks and uncertainties faced by Seagen is contained under the caption "Risk Factors" included in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

1PADCEV [package insert]. Northbrook, IL: Astellas, Inc.

2Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13.

3American Society of Clinical Oncology. Bladder cancer: introduction (10-2017). https://www.cancer.net/cancertypes/bladder-cancer/introduction. Accessed 05-09-2019.

4International Agency for Research on Cancer. Cancer Tomorrow: Bladder. http://gco.iarc.fr/tomorrow. Accessed 07-31-2020.

5ClinicalTrials.gov Identifier: NCT03219333. A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201). https://clinicaltrials.gov/ct2/show/NCT03219333. Accessed on 08-03-2020.

SOURCE Astellas Pharma Inc.

http://www.us.astellas.com

More here:
Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV (enfortumab vedotin-ejfv) in...

Recommendation and review posted by Bethany Smith

LOS ANGELES, United States: QY Research has recently published a research report titled, Global Male Hypogonadism Therapy Market Size, Status and Forecast 2020-2026. This report has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Male Hypogonadism Therapy market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the global Male Hypogonadism Therapy market.

The report includes CAGR, market shares, sales, gross margin, value, volume, and other vital market figures that give an exact picture of the growth of the global Male Hypogonadism Therapy market.

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Male Hypogonadism Therapy market.

Key questions answered in the report:

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Male Hypogonadism Therapy Revenue1.4 Market Analysis by Type1.4.1 Global Male Hypogonadism Therapy Market Size Growth Rate by Type: 2020 VS 20261.4.2 Parenteral1.4.3 Transdermal1.4.4 Oral1.4.5 Others1.5 Market by Application1.5.1 Global Male Hypogonadism Therapy Market Share by Application: 2020 VS 20261.5.2 Hospitals1.5.3 Drugstores1.5.4 Others1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends by Regions2.1 Male Hypogonadism Therapy Market Perspective (2015-2026)2.2 Male Hypogonadism Therapy Growth Trends by Regions2.2.1 Male Hypogonadism Therapy Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Male Hypogonadism Therapy Historic Market Share by Regions (2015-2020)2.2.3 Male Hypogonadism Therapy Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Male Hypogonadism Therapy Market Growth Strategy2.3.6 Primary Interviews with Key Male Hypogonadism Therapy Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Male Hypogonadism Therapy Players by Market Size3.1.1 Global Top Male Hypogonadism Therapy Players by Revenue (2015-2020)3.1.2 Global Male Hypogonadism Therapy Revenue Market Share by Players (2015-2020)3.1.3 Global Male Hypogonadism Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Male Hypogonadism Therapy Market Concentration Ratio3.2.1 Global Male Hypogonadism Therapy Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Male Hypogonadism Therapy Revenue in 20193.3 Male Hypogonadism Therapy Key Players Head office and Area Served3.4 Key Players Male Hypogonadism Therapy Product Solution and Service3.5 Date of Enter into Male Hypogonadism Therapy Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Male Hypogonadism Therapy Historic Market Size by Type (2015-2020)4.2 Global Male Hypogonadism Therapy Forecasted Market Size by Type (2021-2026) 5 Male Hypogonadism Therapy Breakdown Data by Application (2015-2026)5.1 Global Male Hypogonadism Therapy Market Size by Application (2015-2020)5.2 Global Male Hypogonadism Therapy Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Male Hypogonadism Therapy Market Size (2015-2020)6.2 Male Hypogonadism Therapy Key Players in North America (2019-2020)6.3 North America Male Hypogonadism Therapy Market Size by Type (2015-2020)6.4 North America Male Hypogonadism Therapy Market Size by Application (2015-2020) 7 Europe7.1 Europe Male Hypogonadism Therapy Market Size (2015-2020)7.2 Male Hypogonadism Therapy Key Players in Europe (2019-2020)7.3 Europe Male Hypogonadism Therapy Market Size by Type (2015-2020)7.4 Europe Male Hypogonadism Therapy Market Size by Application (2015-2020) 8 China8.1 China Male Hypogonadism Therapy Market Size (2015-2020)8.2 Male Hypogonadism Therapy Key Players in China (2019-2020)8.3 China Male Hypogonadism Therapy Market Size by Type (2015-2020)8.4 China Male Hypogonadism Therapy Market Size by Application (2015-2020) 9 Japan9.1 Japan Male Hypogonadism Therapy Market Size (2015-2020)9.2 Male Hypogonadism Therapy Key Players in Japan (2019-2020)9.3 Japan Male Hypogonadism Therapy Market Size by Type (2015-2020)9.4 Japan Male Hypogonadism Therapy Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Male Hypogonadism Therapy Market Size (2015-2020)10.2 Male Hypogonadism Therapy Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Male Hypogonadism Therapy Market Size by Type (2015-2020)10.4 Southeast Asia Male Hypogonadism Therapy Market Size by Application (2015-2020) 11 India11.1 India Male Hypogonadism Therapy Market Size (2015-2020)11.2 Male Hypogonadism Therapy Key Players in India (2019-2020)11.3 India Male Hypogonadism Therapy Market Size by Type (2015-2020)11.4 India Male Hypogonadism Therapy Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Male Hypogonadism Therapy Market Size (2015-2020)12.2 Male Hypogonadism Therapy Key Players in Central & South America (2019-2020)12.3 Central & South America Male Hypogonadism Therapy Market Size by Type (2015-2020)12.4 Central & South America Male Hypogonadism Therapy Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Eli Lilly13.1.1 Eli Lilly Company Details13.1.2 Eli Lilly Business Overview and Its Total Revenue13.1.3 Eli Lilly Male Hypogonadism Therapy Introduction13.1.4 Eli Lilly Revenue in Male Hypogonadism Therapy Business (2015-2020))13.1.5 Eli Lilly Recent Development13.2 Pfizer13.2.1 Pfizer Company Details13.2.2 Pfizer Business Overview and Its Total Revenue13.2.3 Pfizer Male Hypogonadism Therapy Introduction13.2.4 Pfizer Revenue in Male Hypogonadism Therapy Business (2015-2020)13.2.5 Pfizer Recent Development13.3 AbbVie13.3.1 AbbVie Company Details13.3.2 AbbVie Business Overview and Its Total Revenue13.3.3 AbbVie Male Hypogonadism Therapy Introduction13.3.4 AbbVie Revenue in Male Hypogonadism Therapy Business (2015-2020)13.3.5 AbbVie Recent Development13.4 Novo Nordisk13.4.1 Novo Nordisk Company Details13.4.2 Novo Nordisk Business Overview and Its Total Revenue13.4.3 Novo Nordisk Male Hypogonadism Therapy Introduction13.4.4 Novo Nordisk Revenue in Male Hypogonadism Therapy Business (2015-2020)13.4.5 Novo Nordisk Recent Development13.5 Merck KGaA13.5.1 Merck KGaA Company Details13.5.2 Merck KGaA Business Overview and Its Total Revenue13.5.3 Merck KGaA Male Hypogonadism Therapy Introduction13.5.4 Merck KGaA Revenue in Male Hypogonadism Therapy Business (2015-2020)13.5.5 Merck KGaA Recent Development13.6 Mylan13.6.1 Mylan Company Details13.6.2 Mylan Business Overview and Its Total Revenue13.6.3 Mylan Male Hypogonadism Therapy Introduction13.6.4 Mylan Revenue in Male Hypogonadism Therapy Business (2015-2020)13.6.5 Mylan Recent Development13.7 Bayer13.7.1 Bayer Company Details13.7.2 Bayer Business Overview and Its Total Revenue13.7.3 Bayer Male Hypogonadism Therapy Introduction13.7.4 Bayer Revenue in Male Hypogonadism Therapy Business (2015-2020)13.7.5 Bayer Recent Development13.8 Teva13.8.1 Teva Company Details13.8.2 Teva Business Overview and Its Total Revenue13.8.3 Teva Male Hypogonadism Therapy Introduction13.8.4 Teva Revenue in Male Hypogonadism Therapy Business (2015-2020)13.8.5 Teva Recent Development13.9 Novartis13.9.1 Novartis Company Details13.9.2 Novartis Business Overview and Its Total Revenue13.9.3 Novartis Male Hypogonadism Therapy Introduction13.9.4 Novartis Revenue in Male Hypogonadism Therapy Business (2015-2020)13.9.5 Novartis Recent Development13.10 Abbott13.10.1 Abbott Company Details13.10.2 Abbott Business Overview and Its Total Revenue13.10.3 Abbott Male Hypogonadism Therapy Introduction13.10.4 Abbott Revenue in Male Hypogonadism Therapy Business (2015-2020)13.10.5 Abbott Recent Development13.11 Roche10.11.1 Roche Company Details10.11.2 Roche Business Overview and Its Total Revenue10.11.3 Roche Male Hypogonadism Therapy Introduction10.11.4 Roche Revenue in Male Hypogonadism Therapy Business (2015-2020)10.11.5 Roche Recent Development13.12 Endo International10.12.1 Endo International Company Details10.12.2 Endo International Business Overview and Its Total Revenue10.12.3 Endo International Male Hypogonadism Therapy Introduction10.12.4 Endo International Revenue in Male Hypogonadism Therapy Business (2015-2020)10.12.5 Endo International Recent Development13.13 Ipsen10.13.1 Ipsen Company Details10.13.2 Ipsen Business Overview and Its Total Revenue10.13.3 Ipsen Male Hypogonadism Therapy Introduction10.13.4 Ipsen Revenue in Male Hypogonadism Therapy Business (2015-2020)10.13.5 Ipsen Recent Development13.14 ANI Pharmaceuticals10.14.1 ANI Pharmaceuticals Company Details10.14.2 ANI Pharmaceuticals Business Overview and Its Total Revenue10.14.3 ANI Pharmaceuticals Male Hypogonadism Therapy Introduction10.14.4 ANI Pharmaceuticals Revenue in Male Hypogonadism Therapy Business (2015-2020)10.14.5 ANI Pharmaceuticals Recent Development13.15 TherapeuticsMD10.15.1 TherapeuticsMD Company Details10.15.2 TherapeuticsMD Business Overview and Its Total Revenue10.15.3 TherapeuticsMD Male Hypogonadism Therapy Introduction10.15.4 TherapeuticsMD Revenue in Male Hypogonadism Therapy Business (2015-2020)10.15.5 TherapeuticsMD Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Go here to see the original:
Male Hypogonadism Therapy Market is Booming Worldwide By Top Key Players: Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,...

Recommendation and review posted by Bethany Smith

Los Angeles, United States QY Research offers an overarching research and analysis-based study on the global Hormone Replacement Therapy market, covering growth prospects, market development potential, profitability, supply and demand, and other important subjects. The report presented here comes out as a highly reliable source of information and data on the global Hormone Replacement Therapy market. The researchers and analysts who have prepared the report used an advanced research methodology and authentic primary and secondary sources of market information and data. Readers are provided with clear understanding on the current and future situations of the global Hormone Replacement Therapy market based on revenue, volume, production, trends, technology, innovation, and other critical factors.

Major Key Manufacturers of Hormone Replacement Therapy Market are: , Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva, Novartis, Abbott, Roche, Endo International, Ipsen, ANI Pharmaceuticals, TherapeuticsMD

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart):

https://www.qyresearch.com/sample-form/form/1449847/global-hormone-replacement-therapy-industry

The report offers an in-depth assessment of key market dynamics, the competitive landscape, segments, and regions in order to help readers to become better familiar with the global Hormone Replacement Therapy market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to plan effective strategies for gaining successful in the global Hormone Replacement Therapy market. Importantly, it allows players to gain deep insights into the business development and market growth of leading companies operating in the global Hormone Replacement Therapy market. Players will also be able to know about future market challenges, distribution scenarios, product pricing changes, and other related factors beforehand.

Global Hormone Replacement Therapy Market by Type Segments:

, Estrogen Hormone, Growth Hormone, Thyroid Hormone, Testosterone Hormone, The proportion of estrogen hormone in 2018 is about 50%, and the proportion is in increasing trend from 2014 to 2018.

Global Hormone Replacement Therapy Market by Application Segments:

, Menopause, Hypothyroidism, Growth Hormone Deficiency, Male Hypogonadism, Other Diseases, The most proportion of hormone replacement therapy is used in menopause, and the proportion in 2018 is 46.2%.

Table of Contents

Table of Contents 1 Report Overview1.1 Research Scope1.2 Top Hormone Replacement Therapy Manufacturers Covered: Ranking by Revenue1.3 Market Segment by Type1.3.1 Global Hormone Replacement Therapy Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)1.3.2 Estrogen Hormone1.3.3 Growth Hormone1.3.4 Thyroid Hormone1.3.5 Testosterone Hormone1.4 Market Segment by Application1.4.1 Global Hormone Replacement Therapy Consumption by Application: 2015 VS 2020 VS 20261.4.2 Menopause1.4.3 Hypothyroidism1.4.4 Growth Hormone Deficiency1.4.5 Male Hypogonadism1.4.6 Other Diseases1.5 Study Objectives1.6 Years Considered 2 Global Market Perspective2.1 Global Hormone Replacement Therapy Revenue (2015-2026)2.1.1 Global Hormone Replacement Therapy Revenue (2015-2026)2.1.2 Global Hormone Replacement Therapy Sales (2015-2026)2.2 Hormone Replacement Therapy Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 20262.2.1 Global Hormone Replacement Therapy Sales by Regions (2015-2020)2.2.2 Global Hormone Replacement Therapy Revenue by Regions (2015-2020)2.3 Global Top Hormone Replacement Therapy Regions (Countries) Ranking by Market Size2.4 Hormone Replacement Therapy Industry Trends2.4.1 Hormone Replacement Therapy Market Top Trends2.4.2 Market Drivers2.4.3 Hormone Replacement Therapy Market Challenges 2.4.4 Porters Five Forces Analysis2.4.5 Primary Interviews with Key Hormone Replacement Therapy Players: Views for Future 3 Competitive Landscape by Manufacturers3.1 Global Top Hormone Replacement Therapy Manufacturers by Sales (2015-2020)3.1.1 Global Hormone Replacement Therapy Sales by Manufacturers (2015-2020)3.1.2 Global Hormone Replacement Therapy Sales Market Share by Manufacturers (2015-2020)3.1.3 Global 5 and 10 Largest Manufacturers by Hormone Replacement Therapy Sales in 20193.2 Global Top Manufacturers Hormone Replacement Therapy by Revenue3.2.1 Global Hormone Replacement Therapy Revenue by Manufacturers (2015-2020)3.2.2 Global Hormone Replacement Therapy Revenue Share by Manufacturers (2015-2020)3.2.3 Global Hormone Replacement Therapy Market Concentration Ratio (CR5 and HHI)3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Replacement Therapy as of 2019)3.4 Global Hormone Replacement Therapy Average Selling Price (ASP) by Manufacturers3.5 Key Manufacturers Hormone Replacement Therapy Plants/Factories Distribution and Area Served3.6 Date of Key Manufacturers Enter into Hormone Replacement Therapy Market3.7 Key Manufacturers Hormone Replacement Therapy Product Offered 3.8 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type4.1 Global Hormone Replacement Therapy Historic Market Review by Type (2015-2020)4.1.2 Global Hormone Replacement Therapy Sales Market Share by Type (2015-2020)4.1.3 Global Hormone Replacement Therapy Revenue Market Share by Type (2015-2020)4.1.4 Hormone Replacement Therapy Price by Type (2015-2020)4.1 Global Hormone Replacement Therapy Market Estimates and Forecasts by Type (2021-2026)4.2.2 Global Hormone Replacement Therapy Sales Forecast by Type (2021-2026)4.2.3 Global Hormone Replacement Therapy Revenue Forecast by Type (2021-2026)4.2.4 Hormone Replacement Therapy Price Forecast by Type (2021-2026) 5 Global Hormone Replacement Therapy Market Size by Application5.1 Global Hormone Replacement Therapy Historic Market Review by Application (2015-2020)5.1.2 Global Hormone Replacement Therapy Sales Market Share by Application (2015-2020)5.1.3 Global Hormone Replacement Therapy Revenue Market Share by Application (2015-2020)5.1.4 Hormone Replacement Therapy Price by Application (2015-2020)5.2 Global Hormone Replacement Therapy Market Estimates and Forecasts by Application (2021-2026)5.2.2 Global Hormone Replacement Therapy Sales Forecast by Application (2021-2026)5.2.3 Global Hormone Replacement Therapy Revenue Forecast by Application (2021-2026)5.2.4 Hormone Replacement Therapy Price Forecast by Application (2021-2026) 6 North America6.1 North America Hormone Replacement Therapy Breakdown Data by Company6.2 North America Hormone Replacement Therapy Breakdown Data by Type6.3 North America Hormone Replacement Therapy Breakdown Data by Application6.4 North America Hormone Replacement Therapy Breakdown Data by Countries6.4.1 North America Hormone Replacement Therapy Sales by Countries6.4.2 North America Hormone Replacement Therapy Revenue by Countries6.4.3 U.S.6.4.4 Canada 7 Europe7.1 Europe Hormone Replacement Therapy Breakdown Data by Company7.2 Europe Hormone Replacement Therapy Breakdown Data by Type7.3 Europe Hormone Replacement Therapy Breakdown Data by Application7.4 Europe Hormone Replacement Therapy Breakdown Data by Countries7.4.1 Europe Hormone Replacement Therapy Sales by Countries7.4.2 Europe Hormone Replacement Therapy Revenue by Countries7.4.3 Germany7.4.4 France7.4.5 U.K.7.4.6 Italy7.4.7 Russia 8 Asia Pacific8.1 Asia Pacific Hormone Replacement Therapy Breakdown Data by Company8.2 Asia Pacific Hormone Replacement Therapy Breakdown Data by Type8.3 Asia Pacific Hormone Replacement Therapy Breakdown Data by Application8.4 Asia Pacific Hormone Replacement Therapy Breakdown Data by Regions8.4.1 Asia Pacific Hormone Replacement Therapy Sales by Regions8.4.2 Asia Pacific Hormone Replacement Therapy Revenue by Regions8.4.3 China8.4.4 Japan8.4.5 South Korea8.4.6 India8.4.7 Australia8.4.8 Taiwan8.4.9 Indonesia8.4.10 Thailand8.4.11 Malaysia8.4.12 Philippines8.4.13 Vietnam 9 Latin America9.1 Latin America Hormone Replacement Therapy Breakdown Data by Company9.2 Latin America Hormone Replacement Therapy Breakdown Data by Type9.3 Latin America Hormone Replacement Therapy Breakdown Data by Application9.4 Latin America Hormone Replacement Therapy Breakdown Data by Countries9.4.1 Latin America Hormone Replacement Therapy Sales by Countries9.4.2 Latin America Hormone Replacement Therapy Revenue by Countries9.4.3 Mexico9.4.4 Brazil9.4.5 Argentina 10 Middle East and Africa10.1 Middle East and Africa Hormone Replacement Therapy Breakdown Data by Type10.2 Middle East and Africa Hormone Replacement Therapy Breakdown Data by Application10.3 Middle East and Africa Hormone Replacement Therapy Breakdown Data by Countries10.3.1 Middle East and Africa Hormone Replacement Therapy Sales by Countries10.3.2 Middle East and Africa Hormone Replacement Therapy Revenue by Countries10.3.3 Turkey10.3.4 Saudi Arabia10.3.5 U.A.E 11 Company Profiles11.1 Eli Lilly11.1.1 Eli Lilly Corporation Information11.1.2 Eli Lilly Business Overview and Total Revenue (2019 VS 2018)11.1.3 Eli Lilly Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.1.4 Eli Lilly Hormone Replacement Therapy Products and Services11.1.5 Eli Lilly SWOT Analysis11.1.6 Eli Lilly Recent Developments11.2 Pfizer11.2.1 Pfizer Corporation Information11.2.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)11.2.3 Pfizer Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.2.4 Pfizer Hormone Replacement Therapy Products and Services11.2.5 Pfizer SWOT Analysis11.2.6 Pfizer Recent Developments11.3 AbbVie11.3.1 AbbVie Corporation Information11.3.2 AbbVie Business Overview and Total Revenue (2019 VS 2018)11.3.3 AbbVie Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.3.4 AbbVie Hormone Replacement Therapy Products and Services11.3.5 AbbVie SWOT Analysis11.3.6 AbbVie Recent Developments11.4 Novo Nordisk11.4.1 Novo Nordisk Corporation Information11.4.2 Novo Nordisk Business Overview and Total Revenue (2019 VS 2018)11.4.3 Novo Nordisk Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.4.4 Novo Nordisk Hormone Replacement Therapy Products and Services11.4.5 Novo Nordisk SWOT Analysis11.4.6 Novo Nordisk Recent Developments11.5 Merck KGaA11.5.1 Merck KGaA Corporation Information11.5.2 Merck KGaA Business Overview and Total Revenue (2019 VS 2018)11.5.3 Merck KGaA Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.5.4 Merck KGaA Hormone Replacement Therapy Products and Services11.5.5 Merck KGaA SWOT Analysis11.5.6 Merck KGaA Recent Developments11.6 Mylan11.6.1 Mylan Corporation Information11.6.2 Mylan Business Overview and Total Revenue (2019 VS 2018)11.6.3 Mylan Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.6.4 Mylan Hormone Replacement Therapy Products and Services11.6.5 Mylan SWOT Analysis11.6.6 Mylan Recent Developments11.7 Bayer11.7.1 Bayer Corporation Information11.7.2 Bayer Business Overview and Total Revenue (2019 VS 2018)11.7.3 Bayer Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.7.4 Bayer Hormone Replacement Therapy Products and Services11.7.5 Bayer SWOT Analysis11.7.6 Bayer Recent Developments11.8 Teva11.8.1 Teva Corporation Information11.8.2 Teva Business Overview and Total Revenue (2019 VS 2018)11.8.3 Teva Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.8.4 Teva Hormone Replacement Therapy Products and Services11.8.5 Teva SWOT Analysis11.8.6 Teva Recent Developments11.9 Novartis11.9.1 Novartis Corporation Information11.9.2 Novartis Business Overview and Total Revenue (2019 VS 2018)11.9.3 Novartis Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.9.4 Novartis Hormone Replacement Therapy Products and Services11.9.5 Novartis SWOT Analysis11.9.6 Novartis Recent Developments11.10 Abbott11.10.1 Abbott Corporation Information11.10.2 Abbott Business Overview and Total Revenue (2019 VS 2018)11.10.3 Abbott Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.10.4 Abbott Hormone Replacement Therapy Products and Services11.10.5 Abbott SWOT Analysis11.10.6 Abbott Recent Developments11.11 Roche11.11.1 Roche Corporation Information11.11.2 Roche Business Overview and Total Revenue (2019 VS 2018)11.11.3 Roche Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.11.4 Roche Hormone Replacement Therapy Products and Services11.11.5 Roche SWOT Analysis11.11.6 Roche Recent Developments11.12 Endo International11.12.1 Endo International Corporation Information11.12.2 Endo International Business Overview and Total Revenue (2019 VS 2018)11.12.3 Endo International Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.12.4 Endo International Hormone Replacement Therapy Products and Services11.12.5 Endo International SWOT Analysis11.12.6 Endo International Recent Developments11.13 Ipsen11.13.1 Ipsen Corporation Information11.13.2 Ipsen Business Overview and Total Revenue (2019 VS 2018)11.13.3 Ipsen Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.13.4 Ipsen Hormone Replacement Therapy Products and Services11.13.5 Ipsen SWOT Analysis11.13.6 Ipsen Recent Developments11.14 ANI Pharmaceuticals11.14.1 ANI Pharmaceuticals Corporation Information11.14.2 ANI Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)11.14.3 ANI Pharmaceuticals Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.14.4 ANI Pharmaceuticals Hormone Replacement Therapy Products and Services11.14.5 ANI Pharmaceuticals SWOT Analysis11.14.6 ANI Pharmaceuticals Recent Developments11.15 TherapeuticsMD11.15.1 TherapeuticsMD Corporation Information11.15.2 TherapeuticsMD Business Overview and Total Revenue (2019 VS 2018)11.15.3 TherapeuticsMD Hormone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.15.4 TherapeuticsMD Hormone Replacement Therapy Products and Services11.15.5 TherapeuticsMD SWOT Analysis11.15.6 TherapeuticsMD Recent Developments 12 Supply Chain and Sales Channels Analysis 12.1 Supply Chain Analysis 12.2 Sales Channels Analysis12.2.1 Hormone Replacement Therapy Sales Channels12.2.2 Hormone Replacement Therapy Distributors12.3 Hormone Replacement Therapy Customers 13 Estimates and Projections by Regions (2021-2026)13.1 Global Hormone Replacement Therapy Sales Forecast (2021-2026)13.1.1 Global Hormone Replacement Therapy Sales Forecast by Regions (2021-2026)13.1.2 Global Hormone Replacement Therapy Revenue Forecast by Regions (2021-2026) 13.2 North America Market Size Forecast (2021-2026)13.2.1 North America Hormone Replacement Therapy Sales Forecast (2021-2026)13.2.2 North America Hormone Replacement Therapy Revenue Forecast (2021-2026)13.2.3 North America Hormone Replacement Therapy Size Forecast by County (2021-2026) 13.3 Europe Market Size Forecast (2021-2026)13.3.1 Europe Hormone Replacement Therapy Sales Forecast (2021-2026)13.3.2 Europe Hormone Replacement Therapy Revenue Forecast (2021-2026)13.3.3 Europe Hormone Replacement Therapy Size Forecast by County (2021-2026) 13.4 Asia Pacific Market Size Forecast (2021-2026)13.4.1 Asia Pacific Hormone Replacement Therapy Sales Forecast (2021-2026)13.4.2 Asia Pacific Hormone Replacement Therapy Revenue Forecast (2021-2026)13.4.3 Asia Pacific Hormone Replacement Therapy Size Forecast by Region (2021-2026) 13.5 Latin America Market Size Forecast (2021-2026)13.5.1 Latin America Hormone Replacement Therapy Sales Forecast (2021-2026)13.5.2 Latin America Hormone Replacement Therapy Revenue Forecast (2021-2026)13.5.3 Latin America Hormone Replacement Therapy Size Forecast by County (2021-2026) 13.6 Middle East and Africa Market Forecast13.6.1 Middle East and Africa Hormone Replacement Therapy Sales Forecast (2021-2026)13.6.2 Middle East and Africa Hormone Replacement Therapy Revenue Forecast (2021-2026)13.6.3 Middle East and Africa Hormone Replacement Therapy Size Forecast by County (2021-2026) 14 Research Findings and Conclusion 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Author Details15.3 Disclaimer

Request Customization of Report @ https://www.qyresearch.com/customize-request/form/1449847/global-hormone-replacement-therapy-industry

Why to Buy this Report?

The report is a perfect example of a detailed and meticulously prepared research study on the global Hormone Replacement Therapy market. It can be customized as per the requirements of the client. It not only caters to market players but also stakeholders and key decision makers looking for extensive research and analysis on the global Hormone Replacement Therapy market.

In Order to place the Purchase Query Click Here at USD(4900): https://www.qyresearch.com/settlement/pre/bf2a42e83f1e0c376eeefa7074678b6b,0,1,global-hormone-replacement-therapy-industry

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the rest here:
Hormone Replacement Therapy Market Size, Trends, Growth, Key Companies, Forecast by 2026|Eli Lilly, Pfizer, AbbVie - Weekly Wall

Recommendation and review posted by Bethany Smith